Sitemap
- Home
- Support from the U.S. Department of Defense Will Accelerate Progress on Vaccine Candidate for COVID-19, IAVI Says
- IAVI Researchers Publish Study on Antibody Responses to HIV Immunogen in Non-human Primates
- Expanding access to monoclonal antibody-based products: A global call to action
- IAVI, Merck KGaA, Darmstadt, Germany, and Serum Institute of India Join Forces to Develop Monoclonal Antibodies for COVID-19 and Ensure Prompt and Equitable Global Access
- What are monoclonal antibodies, and can they treat COVID-19?
- About
- Our Work
- Our Science
- News & Resources
- Latest News
- Scientific Publications
- Feasibility of establishing an HIV vaccine preparedness cohort in a population of the Uganda Police Force Lessons learnt from a prospective study
- A Trial of M72 AS01E Vaccine to Prevent Tuberculosis Reply
- Comparison of HIV Risk Behaviors Between Clinical Trials and Observational Cohorts in Uganda
- Identifying the immune interactions underlying HLA class I disease associations
- Route of Vaccine Administration Alters Antigen Trafficking but Not Innate or Adaptive Immunity
- Mapping Polyclonal Antibody Responses in Non human Primates Vaccinated with HIV Env Trimer Subunit Vaccines
- Assessment of PrEP eligibility and uptake among at risk MSM participating in a HIV 1 vaccine feasibility cohort in coastal Kenya
- Evaluation of antiviral T cell responses and TSCM cells in volunteers enrolled in a phase I HIV 1 subtype C prophylactic vaccine trial in India
- Engineered immunogen binding to alum adjuvant enhances humoral immunity
- HIV 1 gp120 CD4 Induced Antibody Complex Elicits CD4 Binding Site Specific Antibody Response in Mice
- Comparison of retention in observational cohorts and nested simulated HIV vaccine efficacy trials in the key populations in Uganda
- Comparisons of the antibody repertoires of a humanized rodent and humans by high throughput sequencing
- Factors associated with alcohol use before sex among HIV negative female sex workers in Zambia
- Comparing Alcohol Use Disorders Identification Test AUDIT with Timeline Follow Back TLFB DSM 5 and Phosphatidylethanol PEth for the assessment of alcohol misuse among young people in Ugandan fishing communities
- The complex challenges of HIV vaccine development require renewed and expanded global commitment
- Impact of Endemic Infections on HIV Susceptibility in Sub Saharan Africa
- HIV immunoprophylaxis preparing the pathway from proof of concept to policy decision and use
- An MPER antibody neutralizes HIV 1 using germline features shared among donors
- Preferred product characteristics for therapeutic vaccines to improve tuberculosis treatment outcomes Key considerations from World Health Organization consultations
- Vaccination with Glycan Modified HIV NFL Envelope Trimer Liposomes Elicits Broadly Neutralizing Antibodies to Multiple Sites of Vulnerability
- Adeno associated virus vectored immunoprophylaxis to prevent HIV in healthy adults a phase 1 randomised controlled trial
- Simulated vaccine efficacy trials to estimate HIV incidence for actual vaccine clinical trials in key populations in Uganda
- Female sex workers in Kigali Rwanda a key population at risk of HIV sexually transmitted infections and unplanned pregnancy
- VH1 69 Utilizing Antibodies Are Capable of Mediating Non neutralizing Fc Mediated Effector Functions Against the Transmitted Founder gp120
- Capturing the inherent structural dynamics of the HIV 1 envelope glycoprotein fusion peptide
- HIV prevention treatment strategies Current challenges future prospects
- Developability assessment of physicochemical properties and stability profiles of HIV 1 BG505 SOSIP 664 and BG505 SOSIP v4 1 GT1 1 gp140 envelope glycoprotein trimers as candidate vaccine antigens
- Retention of adults from fishing communities in an HIV vaccine preparedness study in Masaka Uganda
- Innate immune recognition of glycans targets HIV nanoparticle immunogens to germinal centers
- HIV 1 subtype diversity transmission networks and transmitted drug resistance amongst acute and early infected MSM populations from Coastal Kenya
- Field performance of PIMA Point of Care Machine for CD4 Enumeration Under a Mobile HIV Counseling and Testing Program in Remote Fishing Communities of Lake Victoria Uganda
- Vaccine Induced Protection from Homologous Tier 2 SHIV Challenge in Nonhuman Primates Depends on Serum Neutralizing Antibody Titers
- Vaccine induced T cell responses do not predict the rate of acquisition after repeated intrarectal SIVmac239 challenges in rhesus macaques
- Dual HLA B 42 and B 81 reactive T cell receptors recognize more diverse HIV 1 Gag escape variants
- Pre exposure prophylaxis rollout in a national public sector program the Kenyan case study
- A randomized trial to assess retention rates using mobile phone reminders versus physical contact tracing in a potential HIV vaccine efficacy population of fishing communities around Lake Victoria Uganda
- HIV 1 vaccine design through minimizing envelope metastability
- Reported willingness to participate in a hypothetical HIV vaccine trial and its translation to actual participation among healthy adults Experience from Kenya
- Enhancing Humoral Responses Against HIV Envelope Trimers via Nanoparticle Delivery with Stabilized Synthetic Liposomes
- First in human randomized controlled trial of an oral replicating adenovirus 26 vector vaccine for HIV 1
- Inhibitory killer cell immunoglobulin like receptors strengthen CD8 T cell mediated control of HIV 1 HCV and HTLV 1
- Recent progress in broadly neutralizing antibodies to HIV
- Design display and immunogenicity of HIV1 gp120 fragment immunogens on virus like particles
- Differential processing of HIV envelope glycans on the virus and soluble recombinant trimer
- Development of broadly neutralizing antibodies in HIV 1 infected elite neutralizers
- Induction of circulating T follicular helper cells and regulatory T cells correlating with HIV 1 gp120 variable loop antibodies by a subtype C prophylactic vaccine tested in a Phase I trial in India
- Characterization of the membrane bound form of the chimeric B C recombinant HIV 1 Env LT5 J4b12C
- Precursor Frequency and Affinity Determine B Cell Competitive Fitness in Germinal Centers Tested with Germline Targeting HIV Vaccine Immunogens
- Bacterially expressed HIV 1 gp120 outer domain fragment immunogens with improved stability and affinity for CD4 binding site neutralizing antibodies
- An Empiric Risk Score to Guide PrEP Targeting Among MSM in Coastal Kenya
- Glycan Masking Focuses Immune Responses to the HIV 1 CD4 Binding Site and Enhances Elicitation of VRC01 Class Precursor Antibodies
- Structure Guided Redesign Improves NFL HIV Env Trimer Integrity and Identifies an Inter Protomer Disulfide Permitting Post Expression Cleavage
- Array
- The human naive B cell repertoire contains distinct subclasses for a germline targeting HIV 1 vaccine immunogen
- HIV transmission in discordant couples in Africa in the context of antiretroviral therapy availability
- Evaluation of a mosaic HIV 1 vaccine in a multicentre randomised double blind placebo controlled phase 1 2a clinical trial APPROACH and in rhesus monkeys NHP 13 19
- Cell surface ectodomain integrity of a subset of functional HIV 1 envelopes is dependent on a conserved hydrophilic domain containing region in their C terminal tail
- Frequencies of Circulating Th1 Biased T Follicular Helper Cells in Acute HIV 1 Infection Correlate with the Development of HIV Specific Antibody Responses and Lower Set Point Viral Load
- Antisense Derived HIV 1 Cryptic Epitopes Are Not Major Drivers of Viral Evolution during the Acute Phase of Infection
- Prediction of extended high viremia among newly HIV 1 infected persons in sub Saharan Africa
- Risk of heterosexual HIV transmission attributable to sexually transmitted infections and non specific genital inflammation in Zambian discordant couples 1994 2012
- Targeting the HIV 1 spike and co receptor with bi and trispecific antibodies for single component broad inhibition of entry
- Strategies for a multi stage neutralizing antibody based HIV vaccine
- Co evolution of HIV Envelope and Apex Targeting Neutralizing Antibody Lineage Provides Benchmarks for Vaccine Design
- Differences in acute retroviral syndrome by HIV 1 subtype in a multicentre cohort study in Africa
- Structural and immunologic correlates of chemically stabilized HIV 1 envelope glycoproteins
- Ligand accessibility to the HIV 1 Env co receptor binding site can occur prior to CD4 engagement and is independent of viral tier category
- Cleavage Independent HIV 1 Trimers From CHO Cell Lines Elicit Robust Autologous Tier 2 Neutralizing Antibodies
- Epitope based vaccine design yields fusion peptide directed antibodies that neutralize diverse strains of HIV 1
- Structure of a cleavage independent HIV Env recapitulates the glycoprotein architecture of the native cleaved trimer
- Elicitation of Neutralizing Antibodies Targeting the V2 Apex of the HIV Envelope Trimer in a Wild Type Animal Model
- Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail
- Evaluation of HIV 1 rapid tests and identification of alternative testing algorithms for use in Uganda
- Improving the Immunogenicity of Native like HIV 1 Envelope Trimers by Hyperstabilization
- Global site specific N glycosylation analysis of HIV envelope glycoprotein
- An open label cluster randomised trial to evaluate the effectiveness of a counselling intervention on linkage to care among HIV infected patients in Uganda Study design
- Lack of decline in hepatitis C virus incidence among HIV positive men who have sex with men during 1990 2014
- Schistosoma mansoni and HIV acquisition in fishing communities of Lake Victoria Uganda a nested case control study
- Detection and treatment of Fiebig stage I HIV 1 infection in young at risk women in South Africa a prospective cohort study
- Estimating HIV Incidence in Populations Using Tests for Recent Infection Issues Challenges and the Way Forward
- Structure based design of native like HIV 1 envelope trimers to silence non neutralizing epitopes and eliminate CD4 binding
- Perspective APOBEC mutagenesis in drug resistance and immune escape in HIV and cancer evolution
- A Neutralizing Antibody Recognizing Primarily N Linked Glycan Targets the Silent Face of the HIV Envelope
- Elevated expression impairs HIV control through inhibition of NKG2A expressing cells
- Envelope proteins of two HIV 1 clades induced different epitope specific antibody response
- Utility of Different Adherence Measures for PrEP Patterns and Incremental Value
- cGMP production and analysis of BG505 SOSIP 664 an extensively glycosylated trimeric HIV 1 envelope glycoprotein vaccine candidate
- Synthetic multivalent V3 glycopeptides display enhanced recognition by glycan dependent HIV 1 broadly neutralizing antibodies
- Risky Sex and HIV Acquisition Among HIV Serodiscordant Couples in Zambia 2002 2012 What Does Alcohol Have To Do With It
- Immunoglobulin G1 Allotype Influences Antibody Subclass Distribution in Response to HIV gp140 Vaccination
- Decoding the human immune system to transform the future of global disease prevention and control
- Brief counselling after home based HIV counselling and testing strongly increases linkage to care a cluster randomized trial in Uganda
- Pregnancy and HIV Disease Progression in an Early Infection Cohort from Five African Countries
- Broad neutralization response in a subset of HIV 1 subtype C infected viraemic non progressors from southern India
- Residue centric modeling and design of saccharide and glycoconjugate structures
- The Tetrameric Plant Lectin BanLec Neutralizes HIV through Bidentate Binding to Specific Viral Glycans
- Hidden Lineage Complexity of Glycan Dependent HIV 1 Broadly Neutralizing Antibodies Uncovered by Digital Panning and Native Like gp140 Trimer
- Computational analysis of antibody dynamics identifies recent HIV 1 infection
- Defining HIV 1 transmission clusters based on sequence data
- Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques
- An HIV 1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability
- A Phase 1 Human Immunodeficiency Virus Vaccine Trial for Cross Profiling the Kinetics of Serum and Mucosal Antibody Responses to CN54gp140 Modulated by Two Homologous Prime Boost Vaccine Regimens
- Quantification of the Impact of the HIV 1 Glycan Shield on Antibody Elicitation
- The Landscape of Targeted Immune Responses in the HIV 1 Vaccine Field
- Viral load criteria and threshold optimization to improve HIV incidence assay characteristics
- Rapid elicitation of broadly neutralizing antibodies to HIV by immunization in cows
- Neutralizing antibody affords comparable protection against vaginal and rectal simian human immunodeficiency virus challenge in macaques
- Effect of Schistosoma mansoni Infection on Innate and HIV 1 Specific T Cell Immune Responses in HIV 1 Infected Ugandan Fisher Folk
- Adenovirus based HIV 1 vaccine candidates tested in efficacy trials elicit CD8 T cells with limited breadth of HIV 1 inhibition
- Cryopreservation related loss of antigen specific IFN producing CD4 T cells can skew immunogenicity data in vaccine trials Lessons from a malaria vaccine trial substudy
- Couples voluntary HIV counseling and testing provider training evaluation Zambia
- HIV Envelope Glycoform Heterogeneity and Localized Diversity Govern the Initiation and Maturation of a V2 Apex Broadly Neutralizing Antibody Lineage
- Infection Staging and Incidence Surveillance Applications of High Dynamic Range Diagnostic Immuno Assay Platforms
- High Density Array of Well Ordered HIV 1 Spikes on Synthetic Liposomal Nanoparticles Efficiently Activate B Cells
- Clinical and public health implications of acute and early HIV detection and treatment a scoping review
- Holes in the Glycan Shield of the Native HIV Envelope Are a Target of Trimer Elicited Neutralizing Antibodies
- HIV 1 Cross Reactive Primary Virus Neutralizing Antibody Response Elicited by Immunization in Nonhuman Primates
- Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design
- HIV Broadly Neutralizing Antibodies Taking Good Care Of The 98
- Targeted N glycan deletion at the receptor binding site retains HIV Env NFL trimer integrity and accelerates the elicited antibody response
- HIV 1 transmission networks in high risk fishing communities on the shores of Lake Victoria in Uganda A phylogenetic and epidemiological approach
- Status of vaccine research and development of vaccines for HIV 1
- Glycans Function as Anchors for Antibodies and Help Drive HIV Broadly Neutralizing Antibody Development
- Volunteer motivators for participating in HIV vaccine clinical trials in Nairobi Kenya
- Characterization of a stable HIV 1 B C recombinant soluble and trimeric envelope glycoprotein Env highly resistant to CD4 induced conformational changes
- Fibroblast adapted human CMV vaccines elicit predominantly conventional CD8 T cell responses in humans
- HIV 1 neutralizing antibody induced by simian adenovirus and poxvirus MVA vectored BG505 native like envelope trimers
- Plasma CXCL13 but Not B Cell Frequencies in Acute HIV Infection Predicts Emergence of Cross Neutralizing Antibodies
- Design and crystal structure of a native like HIV 1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo
- Sequential and Simultaneous Immunization of Rabbits with HIV 1 Envelope Glycoprotein SOSIP 664 Trimers from Clades A B and C
- Development and validation of a risk score to assist screening for acute HIV 1 infection among men who have sex with men
- A Comparative Phase I Study of Combination Homologous Subtype C DNA MVA and Env gp140 Protein Adjuvant HIV Vaccines in Two Immunization Regimes
- A Prominent Site of Antibody Vulnerability on HIV Envelope Incorporates a Motif Associated with CCR5 Binding and Its Camouflaging Glycans
- Early Antibody Lineage Diversification and Independent Limb Maturation Lead to Broad HIV 1 Neutralization Targeting the Env High Mannose Patch
- Lactobacillus Deficient Cervicovaginal Bacterial Communities Are Associated with Increased HIV Acquisition in Young South African Women
- Particulate Array of Well Ordered HIV Clade C Env Trimers Elicits Neutralizing Antibodies that Display a Unique V2 Cap Approach
- Glycine Substitution at Helix to Coil Transitions Facilitates the Structural Determination of a Stabilized Subtype C HIV Envelope Glycoprotein
- HIV Vaccine Design to Target Germline Precursors of Glycan Dependent Broadly Neutralizing Antibodies
- Population attributable fraction of incident HIV infections associated with alcohol consumption in fishing communities around Lake Victoria Uganda
- Identification and characterization of a naturally occurring efficiently cleaved membrane bound clade A HIV 1 Env suitable for immunogen design with properties comparable to membrane bound BG505
- High prevalence of curable sexually transmitted infections among pregnant women in a rural county hospital in Kilifi Kenya
- Heterogeneity of HIV incidence a comparative analysis between fishing communities and in a neighbouring rural general population Uganda and implications for HIV control
- Novel approaches in preclinical HIV vaccine research
- Promotion of couples voluntary HIV counseling and testing a comparison of influence networks in Rwanda and Zambia
- Hepatitis B Virus Incidence and Risk Factors Among Human Immunodeficiency Virus 1 Negative Men Who Have Sex With Men in Kenya
- Using facilitated film viewings to engage communities in HIV research involving MSM in Kenya
- Evolution of B cell analysis and Env trimer redesign
- An HIV 1 Env Antibody Complex Focuses Antibody Responses to Conserved Neutralizing Epitopes
- Uptake and Acceptability of Oral HIV Self Testing among Community Pharmacy Clients in Kenya A Feasibility Study
- Covalent Linkage of HIV 1 Trimers to Synthetic Liposomes Elicits Improved B Cell and Antibody Responses
- High Resolution Longitudinal Study of HIV 1 Env Vaccine Elicited B Cell Responses to the Virus Primary Receptor Binding Site Reveals Affinity Maturation and Clonal Persistence
- Impact of pre adapted HIV transmission
- Linkage to HIV care after home based HIV counselling and testing in sub Saharan Africa a systematic review
- Sustained effect of couples HIV counselling and testing on risk reduction among Zambian HIV serodiscordant couples
- Balance between transmitted HLA preadapted and nonassociated polymorphisms is a major determinant of HIV 1 disease progression
- Improving the Expression and Purification of Soluble Recombinant Native Like HIV 1 Envelope Glycoprotein Trimers by Targeted Sequence Changes
- Reducing V3 Antigenicity and Immunogenicity on Soluble Native Like HIV 1 Env SOSIP Trimers
- Single Virus Droplet Microfluidics for High Throughput Screening of Neutralizing Epitopes on HIV Particles
- A shot at AIDS
- Test and treat the early experiences in a clinic serving women at high risk of HIV infection in Kampala
- Dengue and Chikungunya Virus Infections among Young Febrile Adults Evaluated for Acute HIV 1 Infection in Coastal Kenya
- Differential Antibody Responses to Conserved HIV 1 Neutralizing Epitopes in the Context of Multivalent Scaffolds and Native Like gp140 Trimers
- Fitting HIV Prevalence 1981 Onwards for Three Indian States Using the Goals Model and the Estimation and Projection Package
- Lipid interactions and angle of approach to the HIV 1 viral membrane of broadly neutralizing antibody 10E8 Insights for vaccine and therapeutic design
- Thermostability of Well Ordered HIV Spikes Correlates with the Elicitation of Autologous Tier 2 Neutralizing Antibodies
- Moving towards a reliable HIV incidence test current status resources available future directions and challenges ahead
- Semen Bacterial Concentrations and HIV 1 RNA Shedding Among HIV 1 Seropositive Kenyan Men
- Minimally Mutated HIV 1 Broadly Neutralizing Antibodies to Guide Reductionist Vaccine Design
- Stabilization of a soluble native like trimeric form of an efficiently cleaved Indian HIV 1 clade C envelope glycoprotein
- Dual Immunity Concomitantly Suppresses HIV 1 Progression
- First in Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication Competent Sendai Virus Vectored HIV Type 1 Gag Vaccine Induction of Potent T Cell or Antibody Responses in Prime Boost Regimens
- Performance of the Bio Rad Geenius HIV1 2 Supplemental Assay in Detecting Recent HIV Infection and Calculating Population Incidence
- A Phase 1 Study of 4 Live Recombinant Human Cytomegalovirus Towne Toledo Chimera Vaccines in Cytomegalovirus Seronegative Men
- Health Provider Views on Improving Antiretroviral Therapy Adherence Among Men Who Have Sex with Men in Coastal Kenya
- Assessment of Anti HIV 1 Antibodies in Oral and Nasal Compartments of Volunteers From 3 Different Populations
- No Evidence for Association of Defensin Genomic Copy Number with HIV Susceptibility HIV Load during Clinical Latency or Progression to AIDS
- Oral Typhoid Vaccination With Live Attenuated Salmonella Typhi Strain Ty21a Generates Ty21a Responsive and Heterologous Influenza Virus Responsive CD4 and CD8 T Cells at the Human Intestinal Mucosa
- A Broadly Neutralizing Antibody Targets the Dynamic HIV Envelope Trimer Apex via a Long Rigidified and Anionic Hairpin Structure
- Effects of partially dismantling the CD4 binding site glycan fence of HIV 1 Envelope glycoprotein trimers on neutralizing antibody induction
- Diversification in the HIV 1 Envelope Hyper variable Domains V2 V4 and V5 and Higher Probability of Transmitted Founder Envelope Glycosylation Favor the Development of Heterologous Neutralization Breadth
- HIV Controllers Exhibit Enhanced Frequencies of Major Histocompatibility Complex Class II Tetramer Gag Specific CD4 T Cells in Chronic Clade C HIV 1 Infection
- Multiple Antibody Lineages in One Donor Target the Glycan V3 Supersite of the HIV 1 Envelope Glycoprotein and Display a Preference for Quaternary Binding
- The plasma virome of febrile adult Kenyans shows frequent parvovirus B19 infections and a novel arbovirus Kadipiro virus
- Membrane bound modified form of clade B Env JRCSF is suitable for immunogen design as it is efficiently cleaved and displays all the broadly neutralizing epitopes including V2 and C2 domain dependent conformational epitopes
- HIV 1 clade C escapes broadly neutralizing autologous antibodies with N332 glycan specificity by distinct mechanisms
- Dynamics and Correlates of CD8 T Cell Counts in Africans with Primary Human Immunodeficiency Virus Type 1 Infection
- Hormonal Contraceptive Use Among HIV Positive Women and HIV Transmission Risk to Male Partners Zambia 1994 2012
- Association of mutations in V3 C3 domain with enhanced sensitivity of HIV 1 clade C primary envelopes to autologous broadly neutralizing plasma antibodies
- Cross neutralizing anti HIV 1 human single chain variable fragments scFvs against CD4 binding site and N332 glycan identified from a recombinant phage library
- Virus driven Inflammation Is Associated With the Development of bNAbs in Spontaneous Controllers of HIV
- Public community engagement in health research with men who have sex with men in sub Saharan Africa challenges and opportunities
- Priming HIV 1 broadly neutralizing antibody precursors in human Ig loci transgenic mice
- New Vaccines against Epidemic Infectious Diseases
- Presenting native like trimeric HIV 1 antigens with self assembling nanoparticles
- Uncleaved prefusion optimized gp140 trimers derived from analysis of HIV 1 envelope metastability
- Trimeric HIV 1 Env Structures Define Glycan Shields from Clades A B and G
- How intersectional constructions of sexuality culture and masculinity shape identities and sexual decision making among men who have sex with men in coastal Kenya
- HIV 1 Vaccine elicited Antibodies Reverted to Their Inferred Naive Germline Reveal Associations between Binding Affinity and in vivo Activation
- Composition and Antigenic Effects of Individual Glycan Sites of a Trimeric HIV 1 Envelope Glycoprotein
- Conformational Epitope Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV 1 Clade C Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop
- Increased Valency of Conserved mosaic Vaccines Enhances the Breadth and Depth of Epitope Recognition
- Tailored Immunogens Direct Affinity Maturation toward HIV Neutralizing Antibodies
- Sequential Immunization Elicits Broadly Neutralizing Anti HIV 1 Antibodies in Ig Knockin Mice
- Induction of HIV Neutralizing Antibody Lineages in Mice with Diverse Precursor Repertoires
- Deciphering the human antigenome
- Mechanisms of escape from the PGT128 family of anti HIV broadly neutralizing antibodies
- Comparison of HIV incidence estimated in clinical trial and observational cohort settings in a high risk fishing population in Uganda Implications for sample size estimates
- Control of HIV 1 replication in vitro by vaccine induced human CD8 T cells through conserved subdominant Pol epitopes
- Factors associated with dropout in a long term observational cohort of fishing communities around lake Victoria Uganda
- Key gp120 Glycans Pose Roadblocks to the Rapid Development of VRC01 Class Antibodies in an HIV 1 Infected Chinese Donor
- Broad HIV 1 inhibition in vitro by vaccine elicited CD8 T cells in African adults
- Effect of Text Message Phone Call and In Person Appointment Reminders on Uptake of Repeat HIV Testing among Outpatients Screened for Acute HIV Infection in Kenya A Randomized Controlled Trial
- Maturation Pathway from Germline to Broad HIV 1 Neutralizer of a CD4 Mimic Antibody
- Antigen Specific Antibody Glycosylation Is Regulated via Vaccination
- Targeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability
- How I Wish This Thing Was Initiated 100 Years Ago Willingness to Take Daily Oral Pre Exposure Prophylaxis among Men Who Have Sex with Men in Kenya
- Rhesus Macaque B Cell Responses to an HIV 1 Trimer Vaccine Revealed by Unbiased Longitudinal Repertoire Analysis
- HIV 1 Specific CD8 T Cells Exhibit Limited Cross Reactivity during Acute Infection
- Mucosal Humoral Immune Response to SIVmac239 nef Vaccination and Vaginal Challenge
- CXCL13 is a plasma biomarker of germinal center activity
- Deciphering the human immunome
- Structure Guided Redesign Increases the Propensity of HIV Env To Generate Highly Stable Soluble Trimers
- Presenting native like HIV 1 envelope trimers on ferritin nanoparticles improves their immunogenicity
- Model Building and Refinement of a Natively Glycosylated HIV 1 Env Protein by High Resolution Cryoelectron Microscopy
- Kenyan MSM no longer a hidden population
- Targeted screening of at risk adults for acute HIV 1 infection in sub Saharan Africa
- Depression substance abuse and stigma among men who have sex with men in coastal Kenya
- Heterosexual behaviours among men who sell sex to men in coastal Kenya
- Strengthening healthcare providers skills to improve HIV services for MSM in Kenya
- Risk of sexual physical and verbal assaults on men who have sex with men and female sex workers in coastal Kenya
- Changes in sexual risk behavior among MSM participating in a research cohort in coastal Kenya
- Development and pilot testing of an intervention to promote care engagement and adherence among HIV positive Kenyan MSM
- Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV 1 Prevention A Randomized Trial
- Exploring the Potential Health Impact and Cost Effectiveness of AIDS Vaccine within a Comprehensive HIV AIDS Response in Low and Middle Income Countries
- Innate Lymphoid Cells Are Depleted Irreversibly during Acute HIV 1 Infection in the Absence of Viral Suppression
- Hormonal Contraception Pregnancy Breastfeeding and Risk of HIV Disease Progression Among Zambian Women
- Emerging themes for sensitivity training modules of African healthcare workers attending to men who have sex with men a systematic review
- Engineering and Characterization of a Fluorescent Native Like HIV 1 Envelope Glycoprotein Trimer
- Use of Modern Family Planning Methods in Fishing Communities of Lake Victoria Uganda
- A Systematic Review of the Inclusion or Exclusion of Women in HIV Research From Clinical Studies of Antiretrovirals and Vaccines to Cure Strategies
- Crystallographic Identification of Lipid as an Integral Component of the Epitope of HIV Broadly Neutralizing Antibody 4E10
- Fusion peptide of HIV 1 as a site of vulnerability to neutralizing antibody
- The green shoots of a novel training programme progress and identified key actions to providing services to MSM at Kenyan health facilities
- Broadly Neutralizing Antibody Responses in a Large Longitudinal Sub Saharan HIV Primary Infection Cohort
- High Transmitter CD4 T Cell Count Shortly after the Time of Transmission in a Study of African Serodiscordant Couples
- Chemical Cross Linking Stabilizes Native Like HIV 1 Envelope Glycoprotein Trimer Antigens
- A Phase I Double Blind Placebo Controlled Randomized Study of the Safety and Immunogenicity of Electroporated HIV DNA with or without Interleukin 12 in Prime Boost Combinations with an Ad35 HIV Vaccine in Healthy HIV Seronegative African Adults
- Affinity Maturation of a Potent Family of HIV Antibodies Is Primarily Focused on Accommodating or Avoiding Glycans
- Recruitment and retention of women in fishing communities in HIV prevention research
- Antibodies to a conformational epitope on gp41 neutralize HIV 1 by destabilizing the Env spike
- HLA Class II Associated HIV Polymorphisms Predict Escape from CD4 T Cell Responses
- Immunogenicity of Stabilized HIV 1 Envelope Trimers with Reduced Exposure of Non neutralizing Epitopes
- Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV 1 drug resistance an individual patient and sequence level meta analysis
- Knowledge of HIV serodiscordance transmission and prevention among couples in Durban South Africa
- Glycan clustering stabilizes the mannose patch of HIV 1 and preserves vulnerability to broadly neutralizing antibodies
- HIV 1 broadly neutralizing antibody precursor B cells revealed by germline targeting immunogen
- Multiplexed highly accurate DNA sequencing of closely related HIV 1 variants using continuous long reads from single molecule real time sequencing
- Schistosoma mansoni Infection in Ugandan Men Is Associated with Increased Abundance and Function of HIV Target Cells in Blood but Not the Foreskin A Cross sectional Study
- Cryo EM structure of a native fully glycosylated cleaved HIV 1 envelope trimer
- Structural Constraints Determine the Glycosylation of HIV 1 Envelope Trimers
- An efficiently cleaved HIV 1 clade C Env selectively binds to neutralizing antibodies
- Vaccine Elicited Tier 2 HIV 1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan Deficient Patches Proximal to the CD4 Binding Site
- Influences on the Design and Purification of Soluble Recombinant Native Like HIV 1 Envelope Glycoprotein Trimers
- Cleavage independent HIV 1 Env trimers engineered as soluble native spike mimetics for vaccine design
- Identification of Common Features in Prototype Broadly Neutralizing Antibodies to HIV Envelope V2 Apex to Facilitate Vaccine Design
- Authors reply Hormonal contraceptives and HIV Hazards of pronouncing negative studies with low power
- Comprehensive antigenic map of a cleaved soluble HIV 1 envelope trimer
- Hormonal contraception does not increase women s HIV acquisition risk in Zambian discordant couples 1994 2012
- Identification of CD4 Binding Site Dependent Plasma Neutralizing Antibodies in an HIV 1 Infected Indian Individual
- Double Blind Placebo Controlled Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV 1 Gag Pol Nef Fusion Protein and Adenovirus 35 Gag RT Int Nef Vaccine in Healthy HIV Uninfected African Adults
- Implementation of couples voluntary HIV counseling and testing services in Durban South Africa
- HIV vaccine induced sero reactivity a challenge for trial participants researchers and physicians
- Implementation of an electronic fingerprint linked data collection system a feasibility and acceptability study among Zambian female sex workers
- Immunogenetic influences on acquisition of HIV 1 infection consensus findings from two African cohorts point to an enhancer element in IL19 1q32 2
- Vaccine Induced Simian Immunodeficiency Virus Specific CD8 T Cell Responses Focused on a Single Nef Epitope Select for Escape Variants Shortly after Infection
- Understanding Adherence to Daily and Intermittent Regimens of Oral HIV Pre exposure Prophylaxis Among Men Who Have Sex with Men in Kenya
- Magnitude and Kinetics of CD8 T Cell Activation during Hyperacute HIV Infection Impact Viral Set Point
- Effect of seasonal variation on adult clinical laboratory parameters in Rwanda Zambia and Uganda implications for HIV biomedical prevention trials
- Building the Human Vaccines Project strategic management recommendations and summary report of the 15 16 July 2014 business workshop
- Design and structure of two HIV 1 clade C SOSIP 664 trimers that increase the arsenal of native like Env immunogens
- HIV 1 non macrophage tropic R5 envelope glycoproteins are not more tropic for entry into primary CD4 T cells than envelopes highly adapted for macrophages
- Incidence and predictors of attrition from antiretroviral care among adults in a rural HIV clinic in Coastal Kenya a retrospective cohort study
- High incidence of HIV 1 infection in a general population of fishing communities around Lake Victoria Uganda
- Crystal structure of the HIV neutralizing antibody 2G12 in complex with a bacterial oligosaccharide analog of mammalian oligomannose
- High frequency of transmitted HIV 1 Gag HLA class I driven immune escape variants but minimal immune selection over the first year of clade C infection
- An influenza vaccine pill can we swallow it
- Toward a more accurate view of human B cell repertoire by next generation sequencing unbiased repertoire capture and single molecule barcoding
- Transplanting supersites of HIV 1 vulnerability
- Development of a duplex real time RT qPCR assay to monitor genome replication gene expression and gene insert stability during in vivo replication of a prototype live attenuated canine distemper virus vector encoding SIV gag
- Computational design of protein antigens that interact with the CDR H3 loop of HIV broadly neutralizing antibody 2F5
- Primate immune responses to HIV 1 Env formulated in the saponin based adjuvant AbISCO 100 in the presence or absence of TLR9 co stimulation
- Transmitted virus fitness and host T cell responses collectively define divergent infection outcomes in two HIV 1 recipients
- Well ordered trimeric HIV 1 subtype B and C soluble spike mimetics generated by negative selection display native like properties
- Pregnancy incidence and correlates in a clinical trial preparedness study North West Province South Africa
- Creating an African HIV clinical research and prevention trials network HIV prevalence incidence and transmission
- The Potential Impact of Preventive HIV Vaccines in China Results and Benefits of a Multi Province Modeling Collaboration
- Broad and persistent Gag specific CD8 T cell responses are associated with viral control but rarely drive viral escape during primary HIV 1 infection
- Immunization for HIV 1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice
- Canine distemper virus neutralization activity is low in human serum and it is sensitive to an amino acid substitution in the hemagglutinin protein
- Immunogenic Display of Purified Chemically Cross Linked HIV 1 Spikes
- Diverse antibody genetic and recognition properties revealed following HIV 1 envelope glycoprotein immunization
- An assessment of fishing communities around Lake Victoria Uganda as potential populations for future HIV vaccine efficacy studies an observational cohort study
- Structural Repertoire of HIV 1 Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors
- Optimizing parallel induction of HIV type 1 specific antibody and T cell responses by multicomponent subunit vaccines
- Engaging young adult clients of community pharmacies for HIV screening in Coastal Kenya a cross sectional study
- HIV 1 VACCINES Priming a broadly neutralizing antibody response to HIV 1 using a germline targeting immunogen
- HIV 1 VACCINES HIV 1 neutralizing antibodies induced by native like envelope trimers
- CD4 CD8 lymphocyte ratio as a quantitative measure of immunologic health in HIV 1 infection findings from an African cohort with prospective data
- Prevalence Incidence and Clearance of Anogenital Warts in Kenyan Men Reporting High Risk Sexual Behavior Including Men Who Have Sex With Men
- Acceptability and feasibility of repeated mucosal specimen collection in clinical trial participants in Kenya
- The stem of vesicular stomatitis virus G can be replaced with the HIV 1 Env membrane proximal external region without loss of G function or membrane proximal external region antigenic properties
- The immune space a concept and template for rationalizing vaccine development
- HIV 1 receptor binding site directed antibodies using a VH1 2 gene segment orthologue are activated by Env trimer immunization
- Replicative fitness of transmitted HIV 1 drives acute immune activation proviral load in memory CD4 T cells and disease progression
- Independent assessment of candidate HIV incidence assays on specimens in the CEPHIA repository
- A novel live attenuated vesicular stomatitis virus vector displaying conformationally intact functional HIV 1 envelope trimers that elicits potent cellular and humoral responses in mice
- CD4 induced activation in a soluble HIV 1 Env trimer
- Structural evolution of glycan recognition by a family of potent HIV antibodies
- Recombinant HIV envelope trimer selects for quaternary dependent antibodies targeting the trimer apex
- Two classes of broadly neutralizing antibodies within a single lineage directed to the high mannose patch of HIV envelope
- Host genetics and immune control of HIV 1 infection fine mapping for the extended human MHC region in an African cohort
- Long term follow up of study participants from prophylactic HIV vaccine clinical trials in Africa
- Stable 293 T and CHO cell lines expressing cleaved stable HIV 1 envelope glycoprotein trimers for structural and vaccine studies
- Comparing the novel method of assessing PrEP adherence exposure using hair samples to other pharmacologic and traditional measures
- Failure of a novel rapid antigen and antibody combination test to detect antigen positive HIV infection in African adults with early HIV infection
- Diagnosing acute and prevalent HIV 1 infection in young African adults seeking care for fever a systematic review and audit of current practice
- HIV 1 testing of young febrile adults seeking care for fever in sub Sahara Africa
- A next generation cleaved soluble HIV 1 Env trimer BG505 SOSIP 664 gp140 expresses multiple epitopes for broadly neutralizing but not non neutralizing antibodies
- Acute HIV 1 infection is as common as malaria in young febrile adults seeking care in coastal Kenya
- Hyperglycosylated stable core immunogens designed to present the CD4 binding site are preferentially recognized by broadly neutralizing antibodies
- Vaccination with Gag Vif and Nef gene fragments affords partial control of viral replication after mucosal challenge with SIVmac239
- Broad HIV epitope specificity and viral inhibition induced by multigenic HIV 1 adenovirus subtype 35 vector vaccine in healthy uninfected adults
- Promiscuous glycan site recognition by antibodies to the high mannose patch of gp120 broadens neutralization of HIV
- An evaluation of HIV elite controller definitions within a large seroconverter cohort collaboration
- Broad and potent HIV 1 neutralization by a human antibody that binds the gp41 gp120 interface
- Structure of 2G12 Fab2 in complex with soluble and fully glycosylated HIV 1 Env by negative stain single particle electron microscopy
- Conformational dynamics of single HIV 1 envelope trimers on the surface of native virions
- Structure and immune recognition of trimeric pre fusion HIV 1 Env
- Development of broadly neutralizing antibodies from autologous neutralizing antibody responses in HIV infection
- Vaccine elicited human T cells recognizing conserved protein regions inhibit HIV 1
- Profiling human antibody responses by integrated single cell analysis
- Characterization of neutrophil subsets in healthy human pregnancies
- Development of a contemporary globally diverse HIV viral panel by the EQAPOL program
- Development of a luciferase based viral inhibition assay to evaluate vaccine induced CD8 T cell responses
- Host genetics and viral load in primary HIV 1 infection clear evidence for gene by sex interactions
- Immune activation alters cellular and humoral responses to yellow fever 17D vaccine
- Neurovirulence and immunogenicity of attenuated recombinant vesicular stomatitis viruses in nonhuman primates
- CD4 mimetic small molecules sensitize human immunodeficiency virus to vaccine elicited antibodies
- Determinants in V2C2 region of HIV 1 clade C primary envelopes conferred altered neutralization susceptibilities to IgG1b12 and PG9 monoclonal antibodies in a context dependent manner
- Low antibody dependent cellular cytotoxicity responses in Zambians prior to HIV 1 intrasubtype C superinfection
- HIV Type 1 transmission networks among men having sex with men and heterosexuals in Kenya
- Short Communication Defining optimality of a test for recent infection for HIV incidence surveillance
- HIV transmission Selection bias at the heterosexual HIV 1 transmission bottleneck
- Maximising the effect of combination HIV prevention through prioritisation of the people and places in greatest need a modelling study
- Safety adherence and acceptability of intermittent tenofovir emtricitabine as HIV pre exposure prophylaxis PrEP among HIV uninfected Ugandan volunteers living in HIV serodiscordant relationships a randomized clinical trial
- Non immunogenicity of overlapping gag peptides pulsed on autologous cells after vaccination of HIV infected individuals
- Structural delineation of a quaternary cleavage dependent epitope at the gp41 gp120 interface on intact HIV 1 Env trimers
- Broadly neutralizing HIV antibodies define a glycan dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers
- Disease progression by infecting HIV 1 subtype in a seroconverter cohort in sub Saharan Africa
- Evaluation of an empiric risk screening score to identify acute and early HIV 1 infection among MSM in Coastal Kenya
- The effects of somatic hypermutation on neutralization and binding in the PGT121 family of broadly neutralizing HIV antibodies
- Developmental pathway for potent V1V2 directed HIV neutralizing antibodies
- Adaptation of the African couples HIV testing and counseling model for men who have sex with men in the United States an application of the ADAPT ITT framework
- Vaccines that stimulate T cell immunity to HIV 1 the next step
- Accelerating the development of a safe and effective HIV vaccine HIV vaccine case study for the Decade of Vaccines
- Willingness to participate in HIV vaccine efficacy trials among high risk men and women from fishing communities along Lake Victoria in Uganda
- A randomised placebo controlled first in human study of a novel clade C therapeutic peptide vaccine administered ex vivo to autologous white blood cells in HIV infected individuals
- Preventive and therapeutic applications of neutralizing antibodies to Human Immunodeficiency Virus Type 1 HIV 1
- Evaluation of WHO screening algorithm for the presumptive treatment of asymptomatic rectal gonorrhoea and chlamydia infections in at risk MSM in Kenya
- A human antibody to the CD4 binding site of gp120 capable of highly potent but sporadic cross clade neutralization of primary HIV 1
- Vaccine elicited primate antibodies use a distinct approach to the HIV 1 primary receptor binding site informing vaccine redesign
- Global panel of HIV 1 Env reference strains for standardized assessments of vaccine elicited neutralizing antibodies
- Dynamics of viremia in primary HIV 1 infection in Africans insights from analyses of host and viral correlates
- SIV antigen specific effects on immune responses induced by vaccination with DNA electroporation and plasmid IL 12
- Proof of principle for epitope focused vaccine design
- Syphilis treatment response among HIV discordant couples in Zambia and Rwanda
- Fertility goal based counseling increases contraceptive implant and IUD use in HIV discordant couples in Rwanda and Zambia
- Development of replication competent viral vectors for HIV vaccine delivery
- Robust neutralizing antibodies elicited by HIV 1 JRFL envelope glycoprotein trimers in nonhuman primates
- Challenges in providing counselling to MSM in highly stigmatized contexts results of a qualitative study from Kenya
- WHO s new guidelines for antiretroviral treatment
- Crystal structure of a soluble cleaved HIV 1 envelope trimer
- Cryo EM structure of a fully glycosylated soluble cleaved HIV 1 envelope trimer
- High HIV 1 prevalence risk behaviours and willingness to participate in HIV vaccine trials in fishing communities on Lake Victoria Uganda
- Human circulating PD 1 CXCR3 CXCR5 memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses
- Cross sectional survey of treatment practices for urethritis at pharmacies private clinics and government health facilities in coastal Kenya many missed opportunities for HIV prevention
- Influences on trimerization and aggregation of soluble cleaved HIV 1 SOSIP envelope glycoprotein
- Membrane bound SIV envelope trimers are immunogenic in ferrets after intranasal vaccination with a replication competent canine distemper virus vector
- Multidonor analysis reveals structural elements genetic determinants and maturation pathway for HIV 1 neutralization by VRC01 class antibodies
- Chemical cross linking of HIV 1 Env for direct TLR7 8 ligand conjugation compromises recognition of conserved antigenic determinants
- B cells from knock in mice expressing broadly neutralizing HIV antibody b12 carry an innocuous B cell receptor responsive to HIV vaccine candidates
- Immune tolerance negatively regulates B cells in knock in mice expressing broadly neutralizing HIV antibody 4E10
- Immune clearance of highly pathogenic SIV infection
- Immune focusing and enhanced neutralization induced by HIV 1 gp140 chemical cross linking
- Synthetic glycopeptides reveal the glycan specificity of HIV neutralizing antibodies
- Molecular architecture of the uncleaved HIV 1 envelope glycoprotein trimer
- Adherence to antiretroviral therapy and clinical outcomes among young adults reporting high risk sexual behavior including men who have sex with men in coastal Kenya
- Independent expansion of epitope specific plasma cell responses upon HIV 1 envelope glycoprotein immunization
- Viral escape from neutralizing antibodies in early subtype A HIV 1 infection drives an increase in autologous neutralization breadth
- Structural basis for diverse N glycan recognition by HIV 1 neutralizing V1 V2 directed antibody PG16
- Supersite of immune vulnerability on the glycosylated face of HIV 1 envelope glycoprotein gp120
- Antibodies expose multiple weaknesses in the glycan shield of HIV
- Rapid quantitative mapping of anti HIV type 1 envelope serum antibody specificities
- High acceptability of HIV pre exposure prophylaxis but challenges in adherence and use qualitative insights from a phase I trial of intermittent and daily PrEP in at risk populations in Kenya
- Short communication HIV type 1 transmitted drug resistance and evidence of transmission clusters among recently infected antiretroviral naive individuals from Ugandan fishing communities of Lake Victoria
- Safety and immunogenicity of DNA prime and modified vaccinia ankara virus HIV subtype C vaccine boost in healthy adults
- Safety and immunogenicity of DNA and MVA HIV 1 subtype C vaccine prime boost regimens a phase I randomised Trial in HIV uninfected Indian volunteers
- Immunogenicity of seven new recombinant yellow fever viruses 17D expressing fragments of SIVmac239 Gag Nef and Vif in Indian rhesus macaques
- Impact of long term contraceptive promotion on incident pregnancy a randomized controlled trial among HIV positive couples in Lusaka Zambia
- Identification of an HIV 1 clade A envelope that exhibits broad antigenicity and neutralization sensitivity and elicits antibodies targeting three distinct epitopes
- Mining the antibodyome for HIV 1 neutralizing antibodies with next generation sequencing and phylogenetic pairing of heavy light chains
- Accelerating next generation vaccine development for global disease prevention
- Cytomegalovirus vectors violate CD8 T cell epitope recognition paradigms
- High HIV 1 incidence correlates of HIV 1 acquisition and high viral loads following seroconversion among MSM
- A Multiplex Microsphere Based Immunoassay Increases the Sensitivity of SIV Specific Antibody Detection in Serum Samples and Mucosal Specimens Collected from Rhesus Macaques Infected with SIVmac239
- Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti CD4 binding site antibodies
- Low prevalence of transmitted HIV type 1 drug resistance among antiretroviral naive adults in a rural HIV clinic in Kenya
- Design of an Escherichia coli expressed HIV 1 gp120 fragment immunogen that binds to b12 and induces broad and potent neutralizing antibodies
- Factors associated with herpes simplex virus type 2 incidence in a cohort of human immunodeficiency virus type 1 seronegative Kenyan men and women reporting high risk sexual behavior
- Anticipated changes in sexual risk behaviour following vaccination with a low efficacy HIV vaccine survey results from a South African township
- Asymmetric recognition of the HIV 1 trimer by broadly neutralizing antibody PG9
- Rational HIV immunogen design to target specific germline B cell receptors
- Delineating antibody recognition in polyclonal sera from patterns of HIV 1 isolate neutralization
- Heterologous prime boost regimens using rAd35 and rMVA vectors elicit stronger cellular immune responses to HIV proteins than homologous regimens
- HLA B 57 versus HLA B 81 in HIV 1 infection slow and steady wins the race
- HIV 1 RNA may decline more slowly in semen than in blood following initiation of efavirenz based antiretroviral therapy
- Role of transmitted Gag CTL polymorphisms in defining replicative capacity and early HIV 1 pathogenesis
- Lymph node T cell responses predict the efficacy of live attenuated SIV vaccines
- Molecular identification cloning and characterization of transmitted founder HIV 1 subtype A D and A D infectious molecular clones
- Immunization of macaques with soluble HIV type 1 and influenza virus envelope glycoproteins results in a similarly rapid contraction of peripheral B cell responses after boosting
- A Blueprint for HIV Vaccine Discovery
- Cumulative impact of host and viral factors on HIV 1 viral load control during early infection
- Structural insights into key sites of vulnerability on HIV 1 Env and influenza HA
- A phase I double blind placebo controlled randomized study of a multigenic HIV 1 adenovirus subtype 35 vector vaccine in healthy uninfected adults
- Broadly neutralizing antibodies against HIV 1 templates for a vaccine
- Highly potent HIV specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo
- Complex type N glycan recognition by potent broadly neutralizing HIV antibodies
- Structure guided alterations of the gp41 directed HIV 1 broadly neutralizing antibody 2F5 reveal new properties regarding its neutralizing function
- Optimization and qualification of an 8 color intracellular cytokine staining assay for quantifying T cell responses in rhesus macaques for pre clinical vaccine studies
- Anti HIV B Cell lines as candidate vaccine biosensors
- A DNA based candidate HIV vaccine delivered via in vivo electroporation induces CD4 responses toward the 4 7 binding V2 loop of HIV gp120 in healthy volunteers
- Protection against high dose highly pathogenic mucosal SIV challenge at very low serum neutralizing titers of the antibody like molecule CD4 IgG2
- Background morbidity in HIV vaccine trial participants from various geographic regions as assessed by unsolicited adverse events
- Safety and adherence to intermittent pre exposure prophylaxis PrEP for HIV 1 in African men who have sex with men and female sex workers
- HIV 1 neutralizing antibodies display dual recognition of the primary and coreceptor binding sites and preferential binding to fully cleaved envelope glycoproteins
- Learning from Nature to design new biomolecules
- Developing standards of care for HIV prevention research in developing countries a case study of 10 research centers in Eastern and Southern Africa
- Broad and potent neutralization of HIV 1 by a gp41 specific human antibody
- Influence of HAART on alternative reading frame immune responses over the course of HIV 1 infection
- A short segment of the HIV 1 gp120 V1 V2 region is a major determinant of resistance to V1 V2 neutralizing antibodies
- Early loss to follow up of recently diagnosed HIV infected adults from routine pre ART care in a rural district hospital in Kenya a cohort study
- Subunit organization of the membrane bound HIV 1 envelope glycoprotein trimer
- HIV epidemic in Asia optimizing and expanding vaccine development
- Lineage specific differences between human and simian immunodeficiency virus regulation of gp120 trimer association and CD4 binding
- A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield
- A trivalent recombinant Ad5 gag pol nef vaccine fails to protect rhesus macaques from infection or control virus replication after a limiting dose heterologous SIV challenge
- HIV vaccine development challenges and opportunities towards solving the HIV vaccine neutralizing antibody problem
- Transactional sex and HIV understanding the gendered structural drivers of HIV in fishing communities in Southern Malawi
- HIV incidence and prevalence among cohorts of women with higher risk behaviour in Bloemfontein and Rustenburg South Africa a prospective study
- Promotion of couples voluntary HIV counselling and testing in Lusaka Zambia by influence network leaders and agents
- Laboratory expansion to large scale international HIV preventive vaccine trials
- Partial enzymatic deglycosylation preserves the structure of cleaved recombinant HIV 1 envelope glycoprotein trimers
- Selective deactivation of serum IgG a general strategy for the enhancement of monoclonal antibody receptor interactions
- High HIV incidence and socio behavioral risk patterns in fishing communities on the shores of Lake Victoria Uganda
- BLyS mediated modulation of naive B cell subsets impacts HIV Env induced antibody responses
- Successes and challenges of HIV prevention in men who have sex with men
- Antiretroviral prophylaxis for HIV prevention in heterosexual men and women
- Differences in HIV natural history among African and non African seroconverters in Europe and seroconverters in sub Saharan Africa
- Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses
- Emergence of fluoroquinolone resistance in Neisseria gonorrhoeae isolates from four clinics in three regions of Kenya
- A nonfucosylated variant of the anti HIV 1 monoclonal antibody b12 has enhanced Fc RIIIa mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques
- A bacterial lipooligosaccharide that naturally mimics the epitope of the HIV neutralizing antibody 2G12 as a template for vaccine design
- PGV04 an HIV 1 gp120 CD4 binding site antibody is broad and potent in neutralization but does not induce conformational changes characteristic of CD4
- Unliganded HIV 1 gp120 core structures assume the CD4 bound conformation with regulation by quaternary interactions and variable loops
- Genetic variations and heterosexual HIV 1 infection analysis of clustered genes encoding CC motif chemokine ligands
- HIV type 1 in a rural coastal town in Kenya shows multiple introductions with many subtypes and much recombination
- Isolation and characterization of T cells from semen
- Determinants of the higher order association of the restriction factor TRIM5alpha and other tripartite motif TRIM proteins
- Computational design of high affinity epitope scaffolds by backbone grafting of a linear epitope
- An engineered mutant of HIV 1 gp120 formulated with adjuvant Quil A promotes elicitation of antibody responses overlapping the CD4 binding site
- Neutralizing epitopes in the membrane proximal external region of HIV 1 gp41 are influenced by the transmembrane domain and the plasma membrane
- Subtle alteration of residues including N linked glycans in V2 loop modulate HIV 1 neutralization by PG9 and PG16 monoclonal antibodies
- Biochemically defined HIV 1 envelope glycoprotein variant immunogens display differential binding and neutralizing specificities to the CD4 binding site
- DNA Ad5 vaccination with SIV epitopes induced epitope specific CD4 T cells but few subdominant epitope specific CD8 T cells
- How can HIV type 1 Env immunogenicity be improved to facilitate antibody based vaccine development
- Prevalence of seroconversion symptoms and relationship to set point viral load findings from a subtype C epidemic 1995 2009
- Influence network effectiveness in promoting couples HIV voluntary counseling and testing in Kigali Rwanda
- Enhanced HIV 1 neutralization by antibody heteroligation
- Identifying at risk populations in Kenya and South Africa HIV incidence in cohorts of men who report sex with men sex workers and youth
- Structure of HIV 1 gp120 V1 V2 domain with broadly neutralizing antibody PG9
- Evidence against extracellular exposure of a highly immunogenic region in the C terminal domain of the simian immunodeficiency virus gp41 transmembrane protein
- Intra and inter clade cross reactivity by HIV 1 Gag specific T cells reveals exclusive and commonly targeted regions implications for current vaccine trials
- Disparate associations of HLA class I markers with HIV 1 acquisition and control of viremia in an African population
- A novel self replicating chimeric lentivirus like particle
- Diagnosis of latent tuberculosis infection among HIV discordant partners using interferon gamma release assays
- Rapid development of glycan specific broad and potent anti HIV 1 gp120 neutralizing antibodies in an R5 SIV HIV chimeric virus infected macaque
- Modeling the impact on the HIV epidemic of treating discordant couples with antiretrovirals to prevent transmission
- Role of donor genital tract HIV 1 diversity in the transmission bottleneck
- Env glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV 1 infection by neutralizing antibodies and entry inhibitors
- Structure based design of a protein immunogen that displays an HIV 1 gp41 neutralizing epitope
- International seroepidemiology of adenovirus serotypes 5 26 35 and 48 in pediatric and adult populations
- HIV incidence and risk factors for acquisition in HIV discordant couples in Masaka Uganda an HIV vaccine preparedness study
- Local residents trained as influence agents most effective in persuading African couples on HIV counseling and testing
- Prevalence of specific neutralizing antibodies against Sendai virus in populations from different geographic areas implications for AIDS vaccine development using Sendai virus vectors
- A passion for global vaccines
- A prospective study of frequency and correlates of intimate partner violence among African heterosexual HIV serodiscordant couples
- Seroprevalence predictors and estimated incidence of maternal and neonatal Herpes Simplex Virus type 2 infection in semi urban women in Kilifi Kenya
- Functional stability of unliganded envelope glycoprotein spikes among isolates of human immunodeficiency virus type 1 HIV 1
- A directed molecular evolution approach to improved immunogenicity of the HIV 1 envelope glycoprotein
- Increased risk of HIV 1 transmission in pregnancy a prospective study among African HIV 1 serodiscordant couples
- HIV and syphilis prevalence and associated risk factors among fishing communities of Lake Victoria Uganda
- Helical peptide arrays for lead identification and interaction site mapping
- A panel of IgG1 b12 variants with selectively diminished or enhanced affinity for Fc receptors to define the role of effector functions in protection against HIV
- Broad neutralization coverage of HIV by multiple highly potent antibodies
- Computation guided backbone grafting of a discontinuous motif onto a protein scaffold
- A single amino acid substitution in the C4 region in gp120 confers enhanced neutralization of HIV 1 by modulating CD4 binding sites and V3 loop
- In vivo electroporation enhances the immunogenicity of an HIV 1 DNA vaccine candidate in healthy volunteers
- Prevalence and incidence of HIV in a rural community based HIV vaccine preparedness cohort in Masaka Uganda
- The TRIM5 alpha genotype of rhesus macaques affects acquisition of simian immunodeficiency virus SIVsmE660 infection after repeated limiting dose intrarectal challenge
- Enhanced control of pathogenic Simian immunodeficiency virus SIVmac239 replication in macaques immunized with an interleukin 12 plasmid and a DNA prime viral vector boost vaccine regimen
- Role of TRIM5 RING domain E3 ubiquitin ligase activity in capsid disassembly reverse transcription blockade and restriction of simian immunodeficiency virus
- Direct antibody access to the HIV 1 membrane proximal external region positively correlates with neutralization sensitivity
- Human leukocyte antigen variants B 44 and B 57 are consistently favorable during two distinct phases of primary HIV 1 infection in sub Saharan Africans with several viral subtypes
- Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding
- Trimeric HIV 1 glycoprotein gp140 immunogens and native HIV 1 envelope glycoproteins display the same closed and open quaternary molecular architectures
- Activity of broadly neutralizing antibodies including PG9 PG16 and VRC01 against recently transmitted subtype B HIV 1 variants from early and late in the epidemic
- The contribution of HIV discordant relationships to new HIV infections a rebuttal
- Most adults seek urgent healthcare when acquiring HIV 1 and are frequently treated for malaria in coastal Kenya
- Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody
- Measuring human T cell responses in blood and gut samples using qualified methods suitable for evaluation of HIV vaccine candidates in clinical trials
- AIDS vaccines and preexposure prophylaxis is synergy possible
- Knowledge and perceptions of couples voluntary counseling and testing in urban Rwanda and Zambia a cross sectional household survey
- A chimeric HIV 1 envelope glycoprotein trimer with an embedded granulocyte macrophage colony stimulating factor GM CSF domain induces enhanced antibody and T cell responses
- Characterization of a core fragment of the rhesus monkey TRIM5 protein
- A randomized controlled trial to promote long term contraceptive use among HIV serodiscordant and concordant positive couples in Zambia
- High prevalence of quinolone resistance in Neisseria gonorrhoeae in coastal Kenya
- Performance of the Focus HerpeSelect 2 enzyme immunoassay for the detection of herpes simplex virus type 2 antibodies in seven African countries
- Post prostatic massage fluid urine as an alternative to semen for studying male genitourinary HIV 1 shedding
- Reasons for ineligibility in phase 1 and 2A HIV vaccine clinical trials at Kenya AIDS vaccine initiative KAVI Kenya
- Pregnancy rates among female participants in phase I and phase IIA AIDS vaccine clinical trials in Kenya
- Genital HIV 1 RNA predicts risk of heterosexual HIV 1 transmission
- Indeterminate and discrepant rapid HIV test results in couples HIV testing and counselling centres in Africa
- Synthesis and analysis of the membrane proximal external region epitopes of HIV 1
- Ion mobility mass spectrometry for extracting spectra of N glycans directly from incubation mixtures following glycan release application to glycans from engineered glycoforms of intact folded HIV gp120
- Profound early control of highly pathogenic SIV by an effector memory T cell vaccine
- Viral linkage in HIV 1 seroconverters and their partners in an HIV 1 prevention clinical trial
- Estimating HIV incidence among adults in Kenya and Uganda a systematic comparison of multiple methods
- Equivalence of ELISpot assays demonstrated between major HIV network laboratories
- Association of chemokine receptor gene CCR2 CCR5 haplotypes with acquisition and control of HIV 1 infection in Zambians
- Behavioral and social science in HIV vaccine clinical research Workshop report
- Immunotypes of a quaternary site of HIV 1 vulnerability and their recognition by antibodies
- Effects of neighboring glycans on antibody carbohydrate interaction
- The influence of informed consent content on study participants contraceptive knowledge and concerns
- A robust high throughput assay to determine the phagocytic activity of clinical antibody samples
- Exploring the condom gap is supply or demand the limiting factor condom access and use in an urban and a rural setting in Kilifi district Kenya
- Structure based vaccine design in HIV blind men and the elephant
- Beyond detuning 10 years of progress and new challenges in the development and application of assays for HIV incidence estimation
- Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa
- Crystal structure of human antibody 2909 reveals conserved features of quaternary structure specific antibodies that potently neutralize HIV 1
- HIV vaccines current status worldwide and in Africa
- Lack of detectable HIV 1 specific CD8 T cell responses in Zambian HIV 1 exposed seronegative partners of HIV 1 positive individuals
- Impact of a functional KIR2DS4 allele on heterosexual HIV 1 transmission among discordant Zambian couples
- Safety and immunogenicity study of Multiclade HIV 1 adenoviral vector vaccine alone or as boost following a multiclade HIV 1 DNA vaccine in Africa
- The hypervariable HIV 1 capsid protein residues comprise HLA driven CD8 T cell escape mutations and covarying HLA independent polymorphisms
- Replicating viral vectors as HIV vaccines summary report from the IAVI sponsored satellite symposium at the AIDS vaccine 2009 conference
- Vaccination with a modified vaccinia virus Ankara MVA vectored HIV 1 immunogen induces modest vector specific T cell responses in human subjects
- Yeast elicited cross reactive antibodies to HIV Env glycans efficiently neutralize virions expressing exclusively high mannose N linked glycans
- Simian immunodeficiency virus from the sooty mangabey and rhesus macaque is modified with O linked carbohydrate
- Macaque long term nonprogressors resist superinfection with multiple CD8 T cell escape variants of simian immunodeficiency virus
- The B cell response is redundant and highly focused on V1V2 during early subtype C infection in a Zambian seroconverter
- Very few substitutions in a germ line antibody are required to initiate significant domain exchange
- Variable loop glycan dependency of the broad and potent HIV 1 neutralizing antibodies PG9 and PG16
- Antibody 2G12 recognizes di mannose equivalently in domain and nondomain exchanged forms but only binds the HIV 1 glycan shield if domain exchanged
- Human leukocyte antigens and HIV type 1 viral load in early and chronic infection predominance of evolving relationships
- Preexposure chemoprophylaxis for HIV prevention in men who have sex with men
- Safety immunogenicity of tgAAC09 a recombinant adeno associated virus type 2 HIV 1 subtype C vaccine in India
- Couples voluntary counselling and testing and nevirapine use in antenatal clinics in two African capitals a prospective cohort study
- A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV 1 infected individuals
- Elicitation of structure specific antibodies by epitope scaffolds
- Scaffolding to build a rational vaccine design strategy
- High prevalence of Chlamydia trachomatis and Neisseria gonorrhoeae infections among HIV 1 negative men who have sex with men in coastal Kenya
- A nonself sugar mimic of the HIV glycan shield shows enhanced antigenicity
- A phase 2 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 vaccine based on adeno associated virus
- Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques
- Polyreactivity increases the apparent affinity of anti HIV antibodies by heteroligation
- The 2010 scientific strategic plan of the Global HIV Vaccine Enterprise
- Expression system dependent modulation of HIV 1 envelope glycoprotein antigenicity and immunogenicity
- HIV AIDS vaccines and alternate strategies for treatment and prevention
- Polysaccharide mimicry of the epitope of the broadly neutralizing anti HIV antibody 2G12 induces enhanced antibody responses to self oligomannose glycans
- Rational antibody based HIV 1 vaccine design current approaches and future directions
- Macaques vaccinated with simian immunodeficiency virus SIVmac239Delta nef delay acquisition and control replication after repeated low dose heterologous SIV challenge
- Fundamental difference in the content of high mannose carbohydrate in the HIV 1 and HIV 2 lineages
- Design of a non glycosylated outer domain derived HIV 1 gp120 immunogen that binds to CD4 and induces neutralizing antibodies
- Soluble HIV 1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates
- The renaissance in HIV vaccine development future directions
- Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens
- AIDS HIV A boost for HIV vaccine design
- Crystal structure of PG16 and chimeric dissection with somatically related PG9 structure function analysis of two quaternary specific antibodies that effectively neutralize HIV 1
- MHC heterozygote advantage in simian immunodeficiency virus infected Mauritian cynomolgus macaques
- Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV 1
- Heterosexual HIV 1 transmission after initiation of antiretroviral therapy a prospective cohort analysis
- Antibodies against Manalpha1 2 Manalpha1 2 Man oligosaccharide structures recognize envelope glycoproteins from HIV 1 and SIV strains
- Subtype specific conservation of isoleucine 309 in the envelope V3 domain is linked to immune evasion in subtype C HIV 1 infection
- Role of complex carbohydrates in human immunodeficiency virus type 1 infection and resistance to antibody neutralization
- Phase 1 safety and immunogenicity evaluation of ADMVA a multigenic modified vaccinia Ankara HIV 1 B C candidate vaccine
- Phase 1 safety and immunogenicity evaluation of ADVAX a multigenic DNA based clade C B HIV 1 candidate vaccine
- Potent adaptive immune responses induced against HIV 1 gp140 and influenza virus HA by a polyanionic carbomer
- Lack of complex N glycans on HIV 1 envelope glycoproteins preserves protein conformation and entry function
- Haematological and biochemistry laboratory abnormalities associated with splenomegaly in asymptomatic adults in Masaka Uganda implications for HIV biomedical prevention trials
- Anti gp41 antibodies cloned from HIV infected patients with broadly neutralizing serologic activity
- Evaluation of HIV type 1 strains in men having sex with men and in female sex workers in Mombasa Kenya
- Comparison of polyclonal expansion methods to improve the recovery of cervical cytobrush derived T cells from the female genital tract of HIV infected women
- Donor and recipient envs from heterosexual human immunodeficiency virus subtype C transmission pairs require high receptor levels for entry
- HIV type 1 from a patient with baseline resistance to CCR5 antagonists uses drug bound receptor for entry
- Relationship between antibody 2F5 neutralization of HIV 1 and hydrophobicity of its heavy chain third complementarity determining region
- A V3 loop dependent gp120 element disrupted by CD4 binding stabilizes the human immunodeficiency virus envelope glycoprotein trimer
- Structure of HIV 1 gp120 with gp41 interactive region reveals layered envelope architecture and basis of conformational mobility
- Daily acyclovir for HIV 1 disease progression in people dually infected with HIV 1 and herpes simplex virus type 2 a randomised placebo controlled trial
- Accelerating HIV vaccine development
- HIV Selectest enzyme immunoassay and rapid test ability to detect seroconversion following HIV 1 infection
- Viral inhibition assay a CD8 T cell neutralization assay for use in clinical trials of HIV 1 vaccine candidates
- Acyclovir and transmission of HIV 1 from persons infected with HIV 1 and HSV 2
- Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane proximal external region protect against mucosal challenge by simian human immunodeficiency virus SHIVBa L
- A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C modified vaccinia Ankara virus vaccine candidate in Indian volunteers
- Influence of novel CD4 binding defective HIV 1 envelope glycoprotein immunogens on neutralizing antibody and T cell responses in nonhuman primates
- Affordable in house antiretroviral drug resistance assay with good performance in non subtype B HIV 1
- Vaccination with SIVmac239Deltanef activates CD4 T cells in the absence of CD4 T cell loss
- Photoinduced family specific site selective cleavage of TIM barrel proteins
- Structural basis of immune evasion at the site of CD4 attachment on HIV 1 gp120
- Thiyl glycosylation of olefinic proteins S linked glycoconjugate synthesis
- Accuracy of serological assays for detection of recent infection with HIV and estimation of population incidence a systematic review
- Recent trends in clinical trials of vaccines to prevent HIV AIDS
- HIV inactivation by cross linking of photo labeled anti retroviral compounds with HIV reverse transcriptase
- Escape from autologous neutralizing antibodies in acute early subtype C HIV 1 infection requires multiple pathways
- Adaptive mutations in a human immunodeficiency virus type 1 envelope protein with a truncated V3 loop restore function by improving interactions with CD4
- Structure of the HIV 1 gp41 membrane proximal ectodomain region in a putative prefusion conformation
- Broad and potent neutralizing antibodies from an African donor reveal a new HIV 1 vaccine target
- Selective expansion of HIV 1 envelope glycoprotein specific B cell subsets recognizing distinct structural elements following immunization
- Structure based stabilization of HIV 1 gp120 enhances humoral immune responses to the induced co receptor binding site
- Heterosexual transmission of human immunodeficiency virus type 1 subtype C Macrophage tropism alternative coreceptor use and the molecular anatomy of CCR5 utilization
- Evaluation and recommendations on good clinical laboratory practice guidelines for phase I III clinical trials
- Broadly neutralizing human anti HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers
- A conformational switch in human immunodeficiency virus gp41 revealed by the structures of overlapping epitopes recognized by neutralizing antibodies
- Transitions to and from the CD4 bound conformation are modulated by a single residue change in the human immunodeficiency virus type 1 gp120 inner domain
- Effective low titer antibody protection against low dose repeated mucosal SHIV challenge in macaques
- Vector mediated gene transfer engenders long lived neutralizing activity and protection against SIV infection in monkeys
- Neutralizing antibodies generated during natural HIV 1 infection good news for an HIV 1 vaccine
- An African perspective on mucosal immunity and HIV 1
- Soluble CD4 and CD4 mimetic compounds inhibit HIV 1 infection by induction of a short lived activated state
- Is audio computer assisted self interview ACASI useful in risk behaviour assessment of female and male sex workers Mombasa Kenya
- Biochemical and biophysical comparison of cleaved and uncleaved soluble trimeric HIV 1 envelope glycoproteins
- Characteristics of HIV 1 discordant couples enrolled in a trial of HSV 2 suppression to reduce HIV 1 transmission the partners study
- Human immunodeficiency virus type 1 elite neutralizers individuals with broad and potent neutralizing activity identified by using a high throughput neutralization assay together with an analytical selection algorithm
- Sensitivity and specificity of HIV rapid tests used for research and voluntary counselling and testing
- Genetic identity biological phenotype and evolutionary pathways of transmitted founder viruses in acute and early HIV 1 infection
- Chemical modification of proteins at cysteine opportunities in chemistry and biology
- Vaccine induced cellular responses control simian immunodeficiency virus replication after heterologous challenge
- Efficient recovery of high affinity antibodies from a single chain Fab yeast display library
- Adaptation of HIV 1 to human leukocyte antigen class I
- HIV Immune memory downloaded
- Broad diversity of neutralizing antibodies isolated from memory B cells in HIV infected individuals
- HIV 1 and influenza antibodies seeing antigens in new ways
- Evolution of HLA B 5703 HIV 1 escape mutations in HLA B 5703 positive individuals and their transmission recipients
- Willingness to participate in preventive HIV vaccine trials in a community based cohort in south western Uganda
- Community engagement in health research two decades of experience from a research project on HIV in rural Uganda
- A method for identification of HIV gp140 binding memory B cells in human blood
- Broad neutralization of human immunodeficiency virus type 1 HIV 1 elicited from human rhinoviruses that display the HIV 1 gp41 ELDKWA epitope
- A yeast glycoprotein shows high affinity binding to the broadly neutralizing human immunodeficiency virus antibody 2G12 and inhibits gp120 interactions with 2G12 and DC SIGN
- Lessons from IAVI 006 a phase I clinical trial to evaluate the safety and immunogenicity of the pTHr HIVA DNA and MVA HIVA vaccines in a prime boost strategy to induce HIV 1 specific T cell responses in healthy volunteers
- Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge
- Immunology Two in one designer antibodies
- CLSI derived hematology and biochemistry reference intervals for healthy adults in eastern and southern Africa
- Concordant proficiency in measurement of T cell immunity in human immunodeficiency virus vaccine clinical trials by peripheral blood mononuclear cell and enzyme linked immunospot assays in laboratories from three continents
- Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV 1
- Replicating viral vectors as HIV vaccines Summary Report from IAVI Sponsored Satellite Symposium International AIDS Society Conference July 22 2007
- The human immunodeficiency virus type 1 envelope spike of primary viruses can suppress antibody access to variable regions
- Pirate primates in uncharted waters lymphocyte transfers in unrelated MHC matched macaques
- Expanding research capacity and accelerating AIDS vaccine development in Asia
- Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1 infected individuals
- Human immunodeficiency virus type 1 env trimer immunization of macaques and impact of priming with viral vector or stabilized core protein
- Complete characterization of killer Ig like receptor KIR haplotypes in Mauritian cynomolgus macaques novel insights into nonhuman primate KIR gene content and organization
- Antibodies against viruses passive and active immunization
- Glycosylation of gp41 of simian immunodeficiency virus shields epitopes that can be targets for neutralizing antibodies
- Neutralizing activity of antibodies to the V3 loop region of HIV 1 gp120 relative to their epitope fine specificity
- Macaques vaccinated with live attenuated SIV control replication of heterologous virus
- The impact of project closure on HIV incidence and mortality in a cohort of couples in Lusaka Zambia
- Preparedness for AIDS vaccine trials in India
- Importance of the V1 V2 loop region of simian human immunodeficiency virus envelope glycoprotein gp120 in determining the strain specificity of the neutralizing antibody response
- Total synthesis revised structure and biological evaluation of biyouyanagin A and analogues thereof
- Screening for genital and anorectal sexually transmitted infections in HIV prevention trials in Africa
- Modified Kigali combined staging predicts risk of mortality in HIV infected adults in Lusaka Zambia
- Reagent switchable stereoselective beta 1 2 mannoside mannosylation OH 2 of mannose is a privileged acceptor
- Potent antibody mediated neutralization and evolution of antigenic escape variants of simian immunodeficiency virus strain SIVmac239 in vivo
- Human leukocyte antigen class I genotypes in relation to heterosexual HIV type 1 transmission within discordant couples
- Neutralizing antibody and anti retroviral drug sensitivities of HIV 1 isolates resistant to small molecule CCR5 inhibitors
- Demand forecasting for preventive AIDS vaccines economic and policy dimensions
- The relationship between alcohol consumption and unprotected sex among known HIV discordant couples in Rwanda and Zambia
- Structure determination of an anti HIV 1 Fab 447 52D peptide complex from an epitaxially twinned data set
- Allyl sulfides are privileged substrates in aqueous cross metathesis application to site selective protein modification
- Allogeneic lymphocytes persist and traffic in feral MHC matched mauritian cynomolgus macaques
- Regional differences in prevalence of HIV 1 discordance in Africa and enrollment of HIV 1 discordant couples into an HIV 1 prevention trial
- Participation in two phase II prophylactic HIV vaccine trials in the UK
- A glycoconjugate antigen based on the recognition motif of a broadly neutralizing human immunodeficiency virus antibody 2G12 is immunogenic but elicits antibodies unable to bind to the self glycans of gp120
- HIV vaccine research the way forward
- The influence of motivational messages on future planning behaviors among HIV concordant positive and discordant couples in Lusaka Zambia
- Transmission of HIV 1 Gag immune escape mutations is associated with reduced viral load in linked recipients
- Antibody elicited against the gp41 N heptad repeat NHR coiled coil can neutralize HIV 1 with modest potency but non neutralizing antibodies also bind to NHR mimetics
- Safety and immunogenicity of recombinant low dosage HIV 1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara MVA in humans in East Africa
- Efficient HIV 1 transmission from macrophages to T cells across transient virological synapses
- Nonhuman primate models and the failure of the Merck HIV 1 vaccine in humans
- The demographic profile of sero discordant couples enrolled in clinical research in Rwanda and Zambia
- New heterosexually transmitted HIV infections in married or cohabiting couples in urban Zambia and Rwanda an analysis of survey and clinical data
- HIV vaccine trials in India
- Differentiation between isomeric triantennary N linked glycans by negative ion tandem mass spectrometry and confirmation of glycans containing galactose attached to the bisecting beta1 4 GlcNAc residue in N glycans from IgG
- Baseline morbidity in 2 990 adult African volunteers recruited to characterize laboratory reference intervals for future HIV vaccine clinical trials
- A peptide inhibitor of HIV 1 neutralizing antibody 2G12 is not a structural mimic of the natural carbohydrate epitope on gp120
- Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand alpha galactosylceramide
- Toward an AIDS vaccine
- Understanding HIV risks among men who have sex with men in Africa
- Analysis of the human immunodeficiency virus type 1 gp41 membrane proximal external region arrayed on hepatitis B surface antigen particles
- Making autoantibodies safe
- Vaccine protection by live attenuated simian immunodeficiency virus in the absence of high titer antibody responses and high frequency cellular immune responses measurable in the periphery
- Cross subtype antibody and cellular immune responses induced by a polyvalent DNA prime protein boost HIV 1 vaccine in healthy human volunteers
- Targeting the carbohydrates on HIV 1 Interaction of oligomannose dendrons with human monoclonal antibody 2G12 and DC SIGN
- Characterizing clearance of helper adenovirus by a clinical rAAV1 manufacturing process
- N terminal substitutions in HIV 1 gp41 reduce the expression of non trimeric envelope glycoproteins on the virus
- Broad HIV 1 neutralization mediated by CD4 binding site antibodies
- A strategy for accelerating the development of preventive AIDS vaccines
- Science medicine and research in the developing world a perspective
- Promotion of couples voluntary counselling and testing for HIV through influential networks in two African capital cities
- Enrollment and retention of HIV discordant couples in Lusaka Zambia
- Evolution of couples voluntary counseling and testing for HIV in Lusaka Zambia
- The challenges of eliciting neutralizing antibodies to HIV 1 and to influenza virus
- Modeling how many envelope glycoprotein trimers per virion participate in human immunodeficiency virus infectivity and its neutralization by antibody
- HIV 1 infection in high risk men who have sex with men in Mombasa Kenya
- Adaptation of the human immunodeficiency virus type 1 envelope glycoproteins to new world monkey receptors
- Amplified transmission of HIV 1 comparison of HIV 1 concentrations in semen and blood during acute and chronic infection
- The impact of an AIDS vaccine in developing countries a new model and initial results
- HIV 1 rational vaccine design molecular details of b12 gp120 complex structure
- Structures of the CCR5 N terminus and of a tyrosine sulfated antibody with HIV 1 gp120 and CD4
- Overestimation of the South African HIV incidence using the BED IgG assay
- Fc receptor but not complement binding is important in antibody protection against HIV
- Studies of a prophylactic HIV 1 vaccine candidate based on modified vaccinia virus Ankara MVA with and without DNA priming effects of dosage and route on safety and immunogenicity
- Are you on the market a capture recapture enumeration of men who sell sex to men in and around Mombasa Kenya
- Analysis of the neutralization breadth of the anti V3 antibody F425 B4e8 and re assessment of its epitope fine specificity by scanning mutagenesis
- Scientific and policy challenges to development of an AIDS vaccine
- Requirement for CD4 T cell help in maintenance of memory CD8 T cell responses is epitope dependent
- A comparative immunogenicity study in rabbits of disulfide stabilized proteolytically cleaved soluble trimeric human immunodeficiency virus type 1 gp140 trimeric cleavage defective gp140 and monomeric gp120
- Executive summary and recommendations from the WHO UNAIDS IAVI expert group consultation on Phase IIB TOC trials as a novel strategy for evaluation of preventive HIV vaccines 31 January 2 February 2006 IAVI New York USA
- Investigating the utility of the HIV 1 BED capture enzyme immunoassay using cross sectional and longitudinal seroconverter specimens from Africa
- An affinity enhanced neutralizing antibody against the membrane proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10
- Antigenic and immunogenic study of membrane proximal external region grafted gp120 antigens by a DNA prime protein boost immunization strategy
- Exploiting the defensive sugars of HIV 1 for drug and vaccine design
- Specific amino acids in the N terminus of the gp41 ectodomain contribute to the stabilization of a soluble cleaved gp140 envelope glycoprotein from human immunodeficiency virus type 1
- Structural definition of a conserved neutralization epitope on HIV 1 gp120
- Structural basis of enhanced binding of extended and helically constrained peptide epitopes of the broadly neutralizing HIV 1 antibody 4E10
- Endpoints and regulatory issues in HIV vaccine clinical trials lessons from a workshop
- Male circumcision for HIV prevention in men in Rakai Uganda a randomised trial
- Rapid real time detection of acute HIV infection in patients in Africa
- Clinical experience with plasmid DNA and modified vaccinia virus Ankara vectored human immunodeficiency virus type 1 clade A vaccine focusing on T cell induction
- A recombinant non pathogenic Leishmania vaccine expressing human immunodeficiency virus 1 HIV 1 Gag elicits cell mediated immunity in mice and decreases HIV 1 replication in human tonsillar tissue following exposure to HIV 1 infection
- Putting it together AIDS and the millennium development goals
- Estimating the demand for a preventive HIV vaccine why we need to do better Reliable estimates would help in achieving several policy and advocacy objectives
- Novel approach for differential diagnosis of HIV infections in the face of vaccine generated antibodies utility for detection of diverse HIV 1 subtypes
- The cost effectiveness of treating male trichomoniasis to avert HIV transmission in men seeking sexually transmitted disease care in Malawi
- Inhibition of HIV Env binding to cellular receptors by monoclonal antibody 2G12 as probed by Fc tagged gp120
- AIDS vaccine efficacy trials expand capacity and prioritize Throughout Africa Asia and Latin America state of the art clinics and laboratories exist where 4 years ago there were none
- Polyvalent HIV 1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A B C D and E
- Altered primary CD8 T cell response to a modified virus Ankara MVA vectored vaccine in the absence of CD4 T cell help
- Induction of multifunctional human immunodeficiency virus type 1 HIV 1 specific T cells capable of proliferation in healthy subjects by using a prime boost regimen of DNA and modified vaccinia virus Ankara vectored vaccines expressing HIV 1 Gag coupled to
- How do viral and host factors modulate the sexual transmission of HIV Can transmission be blocked
- Phase I clinical trial safety of DNA and modified virus Ankara vectored human immunodeficiency virus type 1 HIV 1 vaccines administered alone and in a prime boost regime to healthy HIV 1 uninfected volunteers
- Standardization of cytokine flow cytometry assays
- HIV vaccine design insights from live attenuated SIV vaccines
- Cytotoxic T lymphocyte escape does not always explain the transient control of simian immunodeficiency virus SIVmac239 viremia in adenovirus boosted and DNA primed Mamu A 01 positive rhesus macaques
- Induction of human immunodeficiency virus type 1 specific T cells by a bluetongue virus tubule vectored vaccine prime recombinant modified virus Ankara boost regimen
- Biodistribution and persistence of an MVA vectored candidate HIV vaccine in SIV infected rhesus macaques and SCID mice
- Vaccine route dose and type of delivery vector determine patterns of primary CD8 T cell responses
- Cytolytic T lymphocytes CTLs from HIV 1 subtype C infected Indian patients recognize CTL epitopes from a conserved immunodominant region of HIV 1 Gag and Nef
- Intermittent low level viremia in very early primary HIV 1 infection
- Determinants of enrollment in a preventive HIV vaccine trial hypothetical versus actual willingness and barriers to participation
- Cross reactivity of anti HIV 1 T cell immune responses among the major HIV 1 clades in HIV 1 positive individuals from 4 continents
- AIDS vaccine development perspectives challenges hopes
- The private demand for an AIDS vaccine in Thailand
- Collecting the essence of man semen collection for HIV transmission studies in sub Saharan Africa
- Factors limiting the immunogenicity of HIV 1 gp120 envelope glycoproteins
- Enhanced immunogenicity using an alphavirus replicon DNA vaccine against human immunodeficiency virus type 1
- Analysis of the neutralizing antibody response elicited in rabbits by repeated inoculation with trimeric HIV 1 envelope glycoproteins
- Anti human immunodeficiency virus type 1 HIV 1 antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane proximal external region of glycoprotein gp41 to neutralize HIV 1
- Novel adeno associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques
- Unwelcome guests with master keys how HIV enters cells and how it can be stopped
- Vaccine development to prevent cytomegalovirus disease report from the National Vaccine Advisory Committee
- A dominant role for CD8 T lymphocyte selection in simian immunodeficiency virus sequence variation
- An AIDS vaccine no time to give up
- Research and development of new vaccines against infectious diseases
- Characterization of the outer domain of the gp120 glycoprotein from human immunodeficiency virus type 1
- DNA vaccines against human immunodeficiency virus type 1
- A novel approach for producing lentiviruses that are limited to a single cycle of infection
- Heterologous human immunodeficiency virus type 1 priming boosting immunization strategies involving replication defective adenovirus and poxvirus vaccine vectors
- Vaccine protection from CD4 T cell loss caused by simian immunodeficiency virus SIV mac251 is afforded by sequential immunization with three unrelated vaccine vectors encoding multiple SIV antigens
- TRIM5alpha mediates the postentry block to N tropic murine leukemia viruses in human cells
- Consequences of cytotoxic T lymphocyte escape common escape mutations in simian immunodeficiency virus are poorly recognized in naive hosts
- A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV 1 integrase
- Viral entry denied
- HIV transmission closing all the doors
- Engineering RENTA a DNA prime MVA boost HIV vaccine tailored for Eastern and Central Africa
- N linked glycosylation in the CXCR4 N terminus inhibits binding to HIV 1 envelope glycoproteins
- AIDS HIV Developing an AIDS vaccine need uncertainty hope
- Mode of action for linear peptide inhibitors of HIV 1 gp120 interactions
- Analysis of the HIV 1 gp41 specific immune response using a multiplexed antibody detection assay
- Structural basis of tyrosine sulfation and VH gene usage in antibodies that recognize the HIV type 1 coreceptor binding site on gp120
- Protective efficacy of a multicomponent vector vaccine in cynomolgus monkeys after intrarectal simian immunodeficiency virus challenge
- Passive immunotherapy in simian immunodeficiency virus infected macaques accelerates the development of neutralizing antibodies
- Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d
- Neutralization sensitivity of a simian human immunodeficiency virus SHIV HXBc2P 3 2N isolated from an infected rhesus macaque with neurological disease
- CD4 induced T 20 binding to human immunodeficiency virus type 1 gp120 blocks interaction with the CXCR4 coreceptor
- Binding and susceptibility to postentry restriction factors in monkey cells are specified by distinct regions of the human immunodeficiency virus type 1 capsid
- Impact of mutations in the coreceptor binding site on human immunodeficiency virus type 1 fusion infection and entry inhibitor sensitivity
- Acute HIV revisited new opportunities for treatment and prevention
- Recent advances in the development of HIV 1 vaccines using replication incompetent adenovirus vectors
- Envelope glycoprotein determinants of increased entry in a pathogenic simian human immunodeficiency virus SHIV HXBc2P 3 2 passaged in monkeys
- Prospects for an AIDS vaccine
- Reversion of CTL escape variant immunodeficiency viruses in vivo
- A human immunodeficiency virus 1 HIV 1 clade A vaccine in clinical trials stimulation of HIV specific T cell responses by DNA and recombinant modified vaccinia virus Ankara MVA vaccines in humans
- Correlation between env V1 V2 region diversification and neutralizing antibodies during primary infection by simian immunodeficiency virus sm in rhesus macaques
- Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small molecule CCR5 inhibitor
- Localized changes in the gp120 envelope glycoprotein confer resistance to human immunodeficiency virus entry inhibitors BMS 806 and 155
- Repeated low dose mucosal simian immunodeficiency virus SIVmac239 challenge results in the same viral and immunological kinetics as high dose challenge a model for the evaluation of vaccine efficacy in nonhuman primates
- The cytoplasmic body component TRIM5alpha restricts HIV 1 infection in Old World monkeys
- Removal of N linked glycosylation sites in the V1 region of simian immunodeficiency virus gp120 results in redirection of B cell responses to V3
- Public health A sound rationale needed for phase III HIV 1 vaccine trials
- Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian human immunodeficiency virus infection
- HIV 1 entry and its inhibition
- Evolution of coreceptor use and CD4 independence in envelope clones derived from SIVsm infected macaques
- Mutations in the C3 region of human and simian immunodeficiency virus envelope have differential effects on viral infectivity replication and CD4 dependency
- Epitope mapping and characterization of a novel CD4 induced human monoclonal antibody capable of neutralizing primary HIV 1 strains
- Role of the gp120 inner domain beta sandwich in the interaction between the human immunodeficiency virus envelope glycoprotein subunits
- Live viral vectors Semliki Forest virus
- Thorny issues in the ethics of AIDS vaccine trials
- The entry of entry inhibitors a fusion of science and medicine
- Structure based targeted deglycosylation of HIV 1 gp120 and effects on neutralization sensitivity and antibody recognition
- Assorted mutations in the envelope gene of simian immunodeficiency virus lead to loss of neutralization resistance against antibodies representing a broad spectrum of specificities
- Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1
- Dynamics of HIV viremia and antibody seroconversion in plasma donors implications for diagnosis and staging of primary HIV infection
- Major histocompatibility complex class I alleles associated with slow simian immunodeficiency virus disease progression bind epitopes recognized by dominant acute phase cytotoxic T lymphocyte responses
- Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 binding region of HIV 1 gp120
- Development of prophylactic AIDS vaccines the current state of affairs
- Medicine The need for a global HIV vaccine enterprise
- Cytolysis by CCR5 using human immunodeficiency virus type 1 envelope glycoproteins is dependent on membrane fusion and can be inhibited by high levels of CD4 expression
- Effects of HIV type 1 envelope glycoprotein proteolytic processing on antigenicity
- Hyperglycosylated mutants of human immunodeficiency virus HIV type 1 monomeric gp120 as novel antigens for HIV vaccine design
- Redox triggered infection by disulfide shackled human immunodeficiency virus type 1 pseudovirions
- Conformational changes in env oligomer induced by an antibody dependent on the V3 loop base
- Genetic fate of recombinant adeno associated virus vector genomes in muscle
- Construction and immunogenicity in a prime boost regimen of a Semliki Forest virus vectored experimental HIV clade A vaccine
- A community randomized controlled trial to investigate impact of improved STD management and behavioural interventions on HIV incidence in rural Masaka Uganda trial design methods and baseline findings
- Development of a DNA MVA HIVA vaccine for Kenya
- Design and tests of an HIV vaccine
- Generation of neutralizing activity against human immunodeficiency virus type 1 in serum by antibody gene transfer
- Design and validation of an enzyme linked immunospot assay for use in clinical trials of candidate HIV vaccines
- The HIV vaccine pipeline from preclinical to phase III
- The quest for an AIDS vaccine is the CD8 T cell approach feasible
- A DNA MVA based candidate human immunodeficiency virus vaccine for Kenya induces multi specific T cell responses in rhesus macaques
- Initial lessons from public private partnerships in drug and vaccine development
- HIV AIDS Vaccine Development Challenges Progress and Future Directions
- HIV vaccine development for the world an idea whose time has come
- Press Releases
- 2020
- IAVI Announces Start of Clinical Trial of Next-Generation HIV Vaccine Candidate
- Support from the U.S. Department of Defense Will Accelerate Progress on Vaccine Candidate for COVID-19, IAVI Says
- IAVI, Merck KGaA, Darmstadt, Germany, and Serum Institute of India Join Forces to Develop Monoclonal Antibodies for COVID-19 and Ensure Prompt and Equitable Global Access
- IAVI and Wellcome issue a global call to action: Monoclonal antibodies for COVID-19 and other diseases could save millions of lives
- IAVI and Scripps Research Join Efforts with NIH to Expedite Development of Globally Accessible and Affordable HIV Antibody Combination Products
- IAVI and Merck Collaborate to Develop Vaccine Against SARS-CoV-2
- COVID-19ワクチン開発のための日本政府による世銀への拠出表明は国際保健改善の模範である、とIAVIが歓迎
- Japan's Commitment to Contribute to the World Bank for COVID-19 Vaccine Research Sets Example and Will Advance Global Health, IAVI Says
- IAVI Welcomes W. Ripley Ballou, M.D., as ADVANCE Program Lead and Principal Investigator
- IAVI and Batavia Biosciences Announce Collaboration on VSV-vector Based Epidemic Preparedness Vaccines
- IAVI Mourns the Passing of Maharaj Kishan Bhan, Respected Scientist, Leader, and Humanitarian
- IAVI Makes Available Unique Dataset and Samples from Pioneering HIV/AIDS Study in Africa to Researchers
- IAVI REPORT – VOL. 22, NO. 2, 2018
- 2019
- EDCTP-Funded Clinical Trial of New TB Vaccine Initiates Vaccinations
- Biofabri, IAVI, and SATVI Collaborate on Clinical Trial of TB Vaccine Candidate MTBVAC in South African Adults
- Award from U.S. Department of Defense to Advance Marburg Virus Vaccine Candidate Development
- GSK candidate vaccine demonstrates sustained level of protection against active pulmonary tuberculosis
- University of Oslo, IAVI, and THSTI to Develop HIV Broadly Neutralizing Antibodies as a Prevention Product for Affordable Global Access
- IAVI and Liverpool School of Tropical Medicine to Partner in Snakebite Consortium
- IAVI Announces First-in-Human Clinical Trial of Native-like HIV Envelope Vaccine Candidate
- 2018
- Six Distinguished Leaders in Global Health Join IAVI Board of Directors
- IAVI and Serum Institute of India to Develop and Manufacture Globally Affordable and Accessible Antibody Products for HIV
- IAVI Announces Clinical Trial of Next-Generation HIV Vaccine Candidate Designed to Induce Antibodies to Block HIV Infection
- IAVI Acquires Aeras TB Vaccine Clinical Programs and Assets
- IAVI and the Public Health Agency of Canada Enter into License Agreement for Technology to Enable Lassa Fever Vaccine Development
- IAVI Mourns the Passing of Dr. Adel A. F. Mahmoud, Vaccine Champion and Public Health Visionary
- CEPI Partners with IAVI to Advance Lassa Fever Vaccines
- IAVI Announces Renewed Support from the Danish Government
- IAVI Welcomes Distinguished New Members to its Board of Directors
- IAVI Remembers HIV Treatment Pioneer David Cooper
- Bonnie Mathieson: Awesome, Fearless and Witty
- 2017
- Research Roundup: IAVI & Partner Discoveries 2017
- Fran Priddy Talks Scientific Challenges at AtlanticLIVE’s Vaccines + Immunity
- New HIV-Prevention Discoveries Harness the Power of Potent Antibodies
- New Findings to Help HIV Scientists Establish ‘Template’ for Potent Antibodies
- Cow Antibodies Yield Important Clues for Developing a Broadly Effective AIDS Vaccine
- New Studies Improve Candidate Vaccine Design for HIV Subtypes Most Common in India and Africa
- IAVI Statement on the US Administration’s Proposed Full Fiscal Year 2018 Budget
- Canadian Researcher Wins Grant to Explore Promising HIV Vaccine Candidate
- IAVI Mourns the Passing of Major Force in HIV Science Dr. Mark Wainberg
- IAVI and Oxford University Initiate Africa-Europe Partnership to Develop an AIDS Vaccine
- IAVI Sponsors Phase I Clinical Trial of a Broadly Neutralizing HIV Antibody
- 2016
- IAVI Awarded Grants to Expedite AIDS Vaccine Development
- New Vaccination Strategies Successfully Coach Immune System to Make Powerful HIV-Neutralizing Antibodies
- IAVI Awarded NIH Contract to Expedite AIDS Vaccine Development
- Eric Goosby Appointed as the New IAVI Board Chair and Anne VanLent Appointed Vice-Chair
- IAVI and Partners Receive Funding from USAID to Advance and Accelerate the Research and Development of an AIDS Vaccine for Africa, with Africa
- Ending AIDS Will Require Innovation in HIV Prevention – Especially a Vaccine
- New HIV-Mimicking Particles That Trigger Immune Response Could Advance AIDS Vaccine Design
- Insights into the Development of Antibodies That Target a Large Portion of HIV Strains Could Advance Vaccine Design
- New Findings in Humans Provide Encouraging Foundation for Upcoming AIDS Vaccine Clinical Trial
- Two novel HIV vaccine platforms demonstrate immunogenicity and good safety profile in phase I clinical study
- IAVI Welcomes New Data from Dapivirine Ring Studies
- Two Leading Experts Join IAVI’s Vaccine Design and Development Teams
- IAVI Announces Continued Funding from Dutch Government
- IAVI Announces Partnership in European HIV Vaccine Alliance
- Study Provides Additional Insights for AIDS Vaccine Design
- Modeling Shows a Vaccine is Essential to Conclusively Ending HIV/AIDS
- 2015
- IAVI and CureVac Partner to Accelerate Development and Testing of AIDS Vaccine Candidates
- Two Studies Outline Progress in HIV Vaccine Design
- IAVI Marks World AIDS Day with Expert Panel Discussion in New York City
- It’s About Time: Together We Can End AIDS
- Updated Guidelines Released to Respect, Protect and Fulfill the Needs of Men Who Have Sex with Men (MSM) in HIV Research
- Francine Ntoumi Joins IAVI Board of Directors
- IAVI Supports New EU-Funded AIDS Vaccine Research Consortium
- Human Vaccines Project Welcomes Janssen as Newest Partner
- Human Vaccines Project Partners with MedImmune to Help Accelerate Research and Development in Infectious Disease and Oncology
- IAVI Names Dr. Mark Feinberg New President and CEO
- IAVI Programs Help Strengthen East Africa’s Health Research Capacity
- AIDS Vaccine R&D Funding – Latest Data Shows Concerning Trends
- Vanderbilt University Medical Center Joins Human Vaccines Project as First Scientific Hub
- IAVI Applauds UNAIDS-Lancet Commission Report on Defeating AIDS
- AIDS Vaccine Candidate Successfully ‘Primes’ Immune System in Animal Models
- India and the Netherlands to collaborate on a joint cohort study on HIV/AIDS
- IAVI CHAIR DR. ALEX GODWIN COUTINHO AWARDED HONORARY DOCTORATE
- NEW METHOD HOLDS PROMISE FOR HIV VACCINE DEVELOPMENT
- MARGIE MCGLYNN TO STEP DOWN AS PRESIDENT AND CEO; SEARCH FOR SUCCESSOR UNDERWAY
- IAVI WELCOMES PROMISING STUDY
- FAST-REPLICATING HIV STRAINS DRIVE INFLAMMATION AND DISEASE PROGRESSION
- IAVI RECEIVES GSK FUNDING FOR THE HUMAN VACCINES PROJECT TO ACCELERATE DEVELOPMENT OF VACCINES FOR INFECTIOUS DISEASES AND CANCER
- GSK GLOBAL VACCINES CHAIRMAN MONCEF SLAOUI JOINS IAVI BOARD OF DIRECTORS
- 2014
- IAVI Welcomes Korean Women against AIDS to India
- IAVI Commemorates Partners Lost on Flight MH17
- IAVI Pays Tribute to Victims of the Malaysia Airlines Tragedy
- Declining Investment Could Slow Research and Rollout of New HIV Prevention Options
- Toward a Human Vaccines Project
- Aids: Don't Die of Prejudice: Compelling Picture of Today's HIV/AIDS Epidemic
- IAVI Commemorates the Life of Dr. Ciro de Quadros, Former Board Member and Public Health Expert
- Together, We Can Achieve a World Without AIDS
- It’s Time For AIDS, TB and Malaria to Go the Way of Smallpox and Polio
- Scientists Find New Point of Attack on HIV for Vaccine Development
- IAVI CEO Margie McGlynn Submits Testimony to U.S. House Appropriations Subcommittee on State, Foreign Operations and Related Programs on Funding for AIDS Vaccine R&D
- IAVI Congratulates New U.S. Global AIDS Coordinator, Deborah Birx
- IAVI Applauds Landmark Study Mapping Evolution of bNAb Against HIV
- IAVI and Partners Initiate Early Clinical Study of New Strategy to Help Prevent HIV
- Achieving a Sustainable End to AIDS Will Require HIV Vaccine, Says Anthony S. Fauci of NIAID
- IAVI Applauds News of Promising New Approach to Vaccine Design
- IAVI Mourns Passing of Dr. Reinhard Kurth, Former Scientific Advisory Committee Chair
- IAVI Congratulates Deborah Birx, MD, on Her Nomination as the Next U.S. Global AIDS Coordinator
- 2013
- IAVI Receives RWJF Grant to Catalyze a Human Vaccines Project
- Alex Coutinho Becomes Chair, Eric Goosby and Lord Fowler Join IAVI Board
- In Memoriam: Nelson Mandela (1918 - 2013)
- World AIDS Day - December 1, 2013: Honoring Their Memories. Finding a Vaccine.
- IAVI Excited About Progress That Detailed Picture of HIV Envelope Protein Can Bring to Fight Against AIDS
- IAVI Shares Recent NIAID Comments in Three Major Publications
- IAVI AND PARTNERS INITIATE PHASE I TRIAL OF A NOVEL AIDS VACCINE REGIMEN
- U.K. Government Pledges Renewed Funding to Support IAVI
- Saluting Nelson Mandela, a Champion of AIDS Awareness
- HIV Research Pioneer Dr. Robin Weiss Appointed Chair of IAVI’s Scientific Advisory Committee
- PrEP Used by Intravenous Drug Users Cuts HIV Infection Risk – IAVI Statement
- Leading Scientists Call for a Human Vaccines Project in Science
- World AIDS Vaccine Day 2013 – IAVI Statement
- NIH Announces It Has Discontinued Immunizations in AIDS Vaccine Clinical Trial HVTN 505
- Product Development Partnerships Applaud Japan’s First Public-Private Partnership to Spearhead Innovation in Global Health
- Researchers Develop a Promising New Technology to Aid HIV Vaccine Design
- IAVI CONGRATULATES MARIJKE WIJNROKS ON APPOINTMENT AT GLOBAL FUND
- IAVI Congratulates Dr. Alex Coutinho and Dr. Peter Piot, Winners of Japan’s Prestigious Africa Health Prize
- IAVI Celebrates International Women’s Day
- New Senior Level Appointments in IAVI’s Medical Affairs Department
- 2012
- World AIDS Day Statement 2012
- IAVI Headquarters temporarily relocated due to Hurricane Sandy
- PATH Malaria Vaccine Initiative Creates New Central Reference Lab
- International Symposium On Accelerating India’s Response to Research for a Preventive HIV Vaccine
- IAVI Welcomes New Members to Board of Directors
- A decade of progress and sustained funding for HIV prevention research provides a pathway for ending AIDS
- Aeras and the International AIDS Vaccine Initiative Partner to Advance Vaccine Research
- IAVI Commends U.S. FDA on Landmark Decision
- IAVI Extends Congratulations to Leading AIDS Vaccine Researchers
- IAVI Welcomes Louis Schwartz as Chief Financial Officer
- Study Reports Data on the Use of Intermittent ARV-Based Pre-Exposure Prophylaxis for HIV Prevention
- IAVI Commemorates World AIDS Vaccine Day
- IAVI, GlycoMimetics, and Glycosensors and Diagnostics Collaborate to Develop Novel AIDS Vaccine Candidate
- AIDS Vaccine Development Leader Esparza Awarded Congressional Medal of Merit
- Leading Global Health Expert Dr. Adel A.F. Mahmoud Joins IAVI Board of Directors
- IAVI Partners With Belgium-Based Biotech
- IAVI, NineSigma Collaborate to Identify New AIDS Vaccines Development Approaches
- 2011
- IAVI and Partners Initiate AIDS Vaccine Trial
- IAVI Applauds Clinton's Support for LGBT Rights
- Getting to Zero calls for Sustained Commitment
- Mary Tydings Joins IAVI Board
- IAVI Congratulates RTS,S on Positive Results
- AIDS Researchers Isolate New Potent and Broadly Effective Antibodies Against HIV
- Report on HIV Prevention Research Funding Says New Investment Critical to Capitalize on HIV Prevention Research Breakthroughs
- IAVI Applauds Results of Studies Evaluating the Use of Antiretrovirals to Prevent HIV
- IAVI Appoints Margaret McGlynn President & Chief Executive Officer
- International AIDS Vaccine Initiative Awarded 10th Consecutive 4-Star Rating by Charity Navigator
- IAVI Marks the Third Decade of the AIDS Pandemic
- IAVI Statement for World AIDS Vaccine Day
- IAVI Congratulates HPTN 052 Collaborators on Positive Trial Results
- IAVI Announces Launch of Fellowship Program in AIDS Vaccine Research and Development
- IAVI Responds to the News of Planned FEM-PrEP Trial Closure
- 40 Organizations Call for Delegates at UN High-Level Meeting to Intensify R&D Investments for New HIV-Prevention Methods
- IAVI Congratulates Its CEO on New Appointment
- THSTI & IAVI Announce New HIV Vaccine Design Program in India
- IAVI and Partners Initiate AIDS Vaccine Trial in Africa
- IAVI Statement on Murder of Ugandan Activist David Kato
- 2010
- Progress in Prevention on World AIDS Day
- Jane Waterman to Join IAVI
- IAVI Commends iPrEX Collaborators on Positive Test Results
- NineSigma and IAVI partner to seek innovative solutions to AIDS vaccine challenges
- Phase I AIDS Vaccine Trial Starts, Testing a Prime-Boost Combinatio
- IAVI-led Team Wins Major Grant to Study HIV-neutralizing Antibodies
- Senior Merck Executive to Head IAVI’s AIDS Vaccine Design and Development Laboratory
- Advances on HIV Prevention Tools Heralded At Conference
- Report Warns Flat Global Funding for HIV Prevention Research May Limit Ability of Researchers to Move Promising Approaches Forward
- IAVI Congratulates CAPRISA on Positive Microbicide Trial Results
- International AIDS Vaccine Initiative Awarded 9th Consecutive 4-Star Rating by Charity Navigator
- Margaret McGlynn, Former President of Global Vaccines at Merck, Joins IAVI Board
- Japan Contributes $10 Million for AIDS Vaccine Development
- IAVI Statement for World AIDS Vaccine Day
- IAVI and Lentigen to Collaborate on Design of Novel AIDS Vaccine Candidate
- David N. Cook joins IAVI as Chief Operating Officer
- 2009
- IAVI Statement in Response to MDP 301 Phase III Trial of a Vaginal Microbicide
- OPEC Fund for International Development Becomes IAVI's Newest Partner
- IAVI 2009 World AIDS Day Statement
- World AIDS Day Community Statement
- Phase I Study of Preventive HIV Vaccine Shows Improved Immune Responses
- Case Studies Offer Inside Look at Effective Ways to Address Global Health Challenges
- IAVI Applauds End of U.S. Travel Ban on HIV-Infected Visitors
- Momentum Seen in AIDS Vaccine Research and Development
- Two Leading Research Institutions Partner to Accelerate the Development of an AIDS Vaccine Candidate
- IAVI Statement on Results of Phase III ALVAC-AIDSVAX Trial in Thailand
- The Scripps Research Institute and IAVI Launch Research Center
- Two New Antibodies Found to Cripple HIV
- Dianne Stewart Joins IAVI
- IAVI Receives 4-Star Charity Navigator Rating for Eighth Year in a Row
- New report finds first decline in HIV vaccine R&D investment in a decade
- IAVI and Theraclone Expand HIV Antibody Discovery Collaboration
- New Advances on the Long Road to the Development of an AIDS Vaccin
- Leading Vaccine Discovery Expert Joins IAVI
- TIME Names Dr. Seth Berkley One of 100 Most Influential People in the World
- 2008
- IAVI Posts $150,000 Challenge on InnoCentive
- IAVI Launches Video Commitments Project
- Phase I Clinical Trial to Test Combination of Two HIV Vaccine Candidates Starts in London
- Call for Volunteers for New AIDS Vaccine Trial
- IAVI Responds to Lancet Article on Intensive Testing and Treatment
- Honorees Herald Opening of New Design Lab
- Congresswoman Supports IAVI Lab Opening
- IAVI Commends UK Government’s Commitment to Ending AIDS
- IAVI Receives 4-Star Charity Navigator Rating
- Elevation Biotech and IAVI Partner To Develop HIV Vaccines
- Scripps and IAVI Launch Neutralizing Antibody Center
- IAVI and Indian Government Announce Results of Phase I AIDS Vaccine Trial
- Inovio Biomedical Expands In Vivo Electroporation License with IAVI
- Mexico City AIDS 2008
- IAVI Launches 2008 AIDS Vaccine Blueprint in Mexico City
- Investment in AIDS Vaccine and Microbicide RandD in 2007
- New UNAIDS Report Reveals Global AIDS Epidemic Slowing
- Global Health Technologies Coalition Statement
- IAVI Responds to NIAID Decision on PAVE 100 Trial
- Leading Vaccine Expert Joins IAVI
- IAVI Awards Latest Innovation Fund Grants
- World AIDS Vaccine Day 2008
- New Markets Tax Credit Helps Finance Lab Construction
- IAVI and CHAVI Team Up on AIDS Vaccine Development
- Latest AIDS Prevention News
- IAVI and VaxDesign Partner to Develop an AIDS Vaccine Clinical Trial in a Test Tube
- Carraguard Microbicide Safe but Not Effective
- IAVI Statement in Response to UK Media Coverage of Baltimore’s Remarks at AAAS
- Further Analysis of STEP AIDS Vaccine Trial Reaffirms Earlier Trend
- 2007
- IAVI teams up with Yahoo! to raise US$100K
- BD Renews Commitment to AIDS Vaccine Research
- IAVI Observes World AIDS Day 2007
- Henry Schein Joins IAVI Corporate Philanthropy Program
- UNAIDS and WHO Revise Stats on Global AIDS Epidemic
- Phambili HIV Vaccine Trial Stopped
- Finance Ministers Support Expanded Funding for AIDS Vaccine R&D
- IAVI Responds to the Announcement that Merck's AIDS Vaccine Candidate Trial Demonstrated a Lack of Efficacy
- University of Tokyo Researcher and IAVI Enter Collaboration
- New Data Redefining Laboratory Reference Ranges in Africa
- Japan's DNAVEC and IAVI Partner on Novel AIDS Vaccine Strategy
- IAVI States Facts Relating to Dismissal of South African Deputy Health Minister
- IAVI Signs Lease To Become First Tenant in New Bioscience Center in Brooklyn
- IAVI and Joaquim Chissano Foundation Sign MOU for Advocacy in Southern Africa
- Spanish Government Contributes One Million Euro for AIDS Vaccine Development
- G8 Leaders Highlight Importance of Effectively Combating Infectious Diseases
- World AIDS Vaccine Day 2007
- India's Department of Biotechnology and IAVI Forge Partnership
- The International AIDS Vaccine Initiative Receives 4-Star Charity Navigator Rating for Sixth Year in a Row
- IAVI Mourns Loss of Ugandan AIDS Vaccine Researcher
- IAVI Welcomes New Canadian Collaborative Initiative
- Vaccines for the Future Act of 2007
- IAVI Encourages Nations Worldwide To Support Advance Market Commitments
- IAVI Mourns the Death of Kenya AIDS Vaccine Initiative Director Job Bwayo
- AIDS Vaccine Clinical Trials in 24 Countries
- 2006
- 2020
- Features
- Progress Toward Global Access to Affordable Antibodies
- International Journal of Epidemiology publishes cohort profile of IAVI’s longitudinal HIV infection studies in Africa
- What we learned from our “Ask the Experts: COVID-19” webinar series
- International Snakebite Awareness Day 2020 – Introducing the SRPNTS Consortium
- Updated: The Effects of COVID-19 on IAVI Clinical Programs
- IAVI Researchers Publish Study on Antibody Responses to HIV Immunogen in Non-human Primates
- How Can We Bridge the Gender Gap for STEM in Africa?
- Expanding access to monoclonal antibody-based products: A global call to action
- Contributing to HIV Vaccine Research in Africa: USAID-Funded Science Capacity Building Partnership with IAVI
- Surveying the HIV Vaccine and Cure Landscape at AIDS 2020 Virtual
- Donor Spotlight: Government of Japan
- Powerful antibodies isolated from recovered donors protect against COVID-19 disease in an animal model
- Exploring the links between HIV and TB research and COVID-19
- End racism if you want to end AIDS.
- Watch IAVI Experts Discuss Accelerating COVID-19 Vaccine Development with Merck
- Webinar Series Explores Community Engagement During COVID-19 and Beyond
- Study finds long-acting injectable HIV prevention option is effective for some populations
- The Effects of COVID-19 on IAVI Clinical Programs
- It’s Time for Increased TB R&D Funding
- United Kingdom Department for International Development (DFID), IAVI’s First Government Funder
- IAVI’s Kundai Chinyenze weighs in on why PrEP isn't meeting expectations for African women
- IAVI and Partners Announce the 6th Global Forum on TB Vaccines in 2021 in Toulouse, France
- IAVI’s Anatoli Kamali provides perspective on how to combat HIV in high-risk communities
- IAVI Report Vol. 23, No. 2, 2019
- Upcoming efficacy trial illustrates the value of African-led science
- HIV Vaccine Design Strategy Shows Promise in Proof-of-Principle Tests
- IAVI Scientists and Partners Discuss Access Pathways for New HIV Prevention Options
- IAVI and TBVI Strengthen Tuberculosis Vaccine Development Pathway
- Working Toward Global Access to Affordable Antibodies
- Donor Spotlight: The Norwegian Government
- Donor Spotlight: United States Agency for International Development
- IAVI Report Vol. 23, No. 1, 2019
- IAVI-Led Study Explores Gene Transfer for HIV Antibody Expression
- Year of Progress Highlights Need for TB Vaccine Research Support
- Donor Spotlight: Netherlands Ministry of Foreign Affairs
- Donor Spotlight: Danida
- IAVI Report Vol. 22, No. 3, 2018
- Antibody-based HIV Prevention: Preparing for Success
- Scientific Advances Spur New Hope for Defeating TB
- HIVR4P 2018
- HIV Prevention: From Innovation to Implementation
- IAVI Report
- HIV Vaccine Awareness Day 2018
- Research Roundup 2017
- IAVI’s Fran Priddy Talks Scientific Challenges at AtlanticLIVE’s Vaccines + Immunity
- New IAVI Collaboration Seeks to Expand Evolutionary Data on Cancer and HIV
- IAVI Partnership with MSD Aims to Improve HIV Prevention for People Who Need it Most
- The Right APPROACH: IAVI Clinical Network Helps Janssen Assess Promising Mosaic HIV Vaccine
- IAVI Takes an Overview of Paris
- The Need for Long-Acting HIV Prevention
- International Women's Day 2016
- International Women's Day 2016 Bulletin
- INTERNATIONAL WOMEN'S DAY 2015: WOMEN>AIDS
- Women Leading the Fight Against HIV/AIDS
- International Women's Day 2015 Bulletin
- IAVI Report
- IAVI in the News
- Scientists build on HIV research in bid to stop snakebite deaths
- Merck, advancing single-dose and oral coronavirus vaccines, could still make Warp Speed: Bloomberg
- Four Ways To Increase Global Access To Promising Monoclonal Antibodies For COVID-19
- Antibodies needed to save lives in Africa
- San Diego biotechs developing COVID-blocking nasal spray with cloned antibodies
- Merck CEO sees human trials for COVID-19 vaccine candidate 'fairly soon'
- Four US Coronavirus Vaccine Trials Will Fail, Health Advisers Predict
- Antibody therapies could be a bridge to a coronavirus vaccine — but will the world benefit?
- COVID-19 Triple Play: Merck Acquiring Themis, Partnering with Ridgeback, IAVI
- Merck Takes 3 Major Shots at COVID-19: Themis, IAVI and Ridgeback Bio
- Dow Jones Surges 600 Points as Merck Works on Vaccine, Restaurant Activity Picks Up
- Merck Teams To Tackle SARS-CoV-2 Vaccine
- Merck, IAVI work to develop COVID-19 vaccine
- Merck partners with nonprofit to develop potential coronavirus vaccine
- Merck bets on viral vector vaccine platforms, plus oral antiviral, in three-way COVID-19 push
- Merck, one of Big Pharma’s biggest players, reveals its COVID-19 vaccine and therapy plans
- Merck leaps into Covid-19 vaccine race, aiming to test two different candidates this year
- Merck in collaboration to develop coronavirus vaccine, with clinical trials to start this year
- The world needs Covid-19 vaccines. It may also be overestimating their power
- Lessons Learned About HIV in Searching for a Coronavirus Vaccine
- Infect volunteers with Covid-19 in the name of research? A proposal lays bare a minefield of issues
- Scores of coronavirus vaccines are in competition — how will scientists choose the best?
- Ana Céspedes: "There are 119 vaccine candidates for COVID-19 with a 6% probability of success” (Spanish)
- HIV vaccine: Scientists call for patience as research continues
- How AIDS vaccine research could help fight COVID-19
- Everything Must Go Right for Big Pharma’s Bet on a Fast Vaccine
- GSK vaccine chief heads for AIDS vaccine initiative
- Up and down the ladder: The latest comings and goings
- Stigma, distancing in slums may impede India's coronavirus fight
- The timetable for a coronavirus vaccine is 18 months. Experts say that's risky
- Why Are We Responding Slower Today Than during the Last Pandemic?
- What the female reproductive tract could tell Kenyan researchers about HIV
- Study points toward progress on TB vaccines
- Researchers rush to test coronavirus vaccine in people without knowing how well it works in animals
- A $100 Million HIV Vaccine Project Failed. But All Hope Is Not Lost
- A Chinese biotech partners with GSK to boost its coronavirus vaccine development
- Sanofi announces it will work with HHS to develop coronavirus vaccine
- For African women at risk of HIV, a woke world is still sound asleep
- Scientists are developing a vaccine against HIV vaccine after the initial results were dismissed
- The search for an effective HIV vaccine continues
- We'll only rest once we get vaccine, say experts despite failed test
- Failed HIV Vaccine?
- Biotech Stocks Swing on Coronavirus Vaccine Hopes
- Coronavirus Is No Ebola, and That Presents a Different Problem
- How fast can biotech come up with a vaccine for the latest outbreak?
- Prof Kaleebu won’t tire until Aids cure is found
- Social media ads are misleading people about the effects of a major HIV prevention drug
- An Ebola vaccine was more than two decades in the making. Here are some key people who made it happen
- ‘Against all odds’: The inside story of how scientists across three continents produced an Ebola vaccine
- To win war against HIV, focus on high risk areas
- YSPH Alumni Play Important Roles in Advancing Ebola Vaccine
- Experimental HIV Vaccine Shows Success in Rabbit Tests, Neutralizes Wide Variety of Strains
- Clinical trial of vaccine shows 49.7% efficacy in preventing pulmonary TB infection
- Vaccine with potential to prevent active TB hailed as game-changer
- Hopes rise for new TB vaccine after early trial shows 'astonishing' results
- GSK's tuberculosis vaccine shows promising results
- New tuberculosis vaccine moves one step closer as a trial of 'game-changer' jab proves it can stop the killer disease flaring up in infected patients
- TB vaccine shows potential to prevent the disease and save lives
- New TB Vaccine Gets More Efficient; Another $30 Million Allotted for Research
- HIV prevention is making progress. And a breakthrough vaccine appears within reach
- India pivotal to global fightback against AIDS, says chief of vaccine initiative
- India Can Be a Global Leader in TB Research
- Kenya to start trial of new vaccine that stops HIV infecting cells
- Snakebite: The Race to Find a Universal Antivenom
- How Rwanda could be the first country to wipe out cervical cancer
- 'It Might Get Worse': Drug Resistance, Dip in Funds May Aggravate Cases of HIV AIDS
- FT Health: Key moment for the NHS
- Vaccines: our greatest hope in defeating AIDS, Ebola, TB, and other infectious diseases
- Why HIV vaccine research is now about much more than HIV
- The number of new HIV cases in India is falling but not fast enough and there’s a risk of resurgence
- At a lab in Faridabad, efforts to develop a vaccine for HIV
- Did Science Miss Its Best Shot at an AIDS Vaccine?
- Research during Ebola vaccine trial: It’s complicated
- India-Netherlands-Sweden collaborative programme on HIV/AIDS research
- Why the world should keep the hope for an HIV vaccine
- Artists Are Using Theater to Raise Awareness About India's HIV Crisis
- Africa Analysis: Capacity building in HIV vaccine R&D
- PSF three decades strong in conducting vaccine research to eradicate HIV epidemic
- The Rise of Broadly Neutralizing Antibodies
- American Generosity Contributes to Global Impact: HIV Vaccine Awareness Day 2018
- Experts call for Africa suited vaccines to boost war on AIDS
- Take as Directed: Pursuing a Vaccine for HIV
- Time for EU to take charge of global health research agenda
- Invest now, change the world later: why funding HIV and TB vaccines research is worth the money
- Saved, Yet Shamed
- Developing an HIV vaccine is probably the biggest challenge : Dr Mark Feinberg
- Women in Science (Hindi language podcast)
- Episode 199: Peter Staley
- Who will answer the call in the next outbreak? Drug makers feel burned by string of vaccine pleas
- Fact Sheets & Publications
- VOICES Newsletter
- Issue 6 - Keeping All Eyes on the Target to End HIV Despite a Pandemic
- Issue 5 - Elevating Communities’ Needs in the HIV Response
- Issue 4 - Meaningful Engagement with Adolescents, Young Women, and Girls in HIV Prevention Research
- Issue 3 - Community Perspectives on the AIDS 2018 Conference
- Issue 2 - Perspectives from Community Liaison Officers
- Issue 1 - HIV Vaccine Awareness Day
- Media Contacts
- Subscribe
- Expanding access to monoclonal antibody-based products: A global call to action
- Our COVID-19 Response
- HIV Vaccine Awareness Day: Eyes on the Target
- IAVI at the 23rd International AIDS Conference
- FRESH in South Africa
- Kenya HIV & Aids research agenda
- HIV Vaccine Awareness Day 2017
- HIVR4P 2016
- AIDS 2016
- World AIDS Day 2015 Bulletin
- HIV Vaccine Awareness Day 2016
- World AIDS Day 2015 (WAD)
- HIV Vaccine Awareness Day 2015 Bulletin
- Capacity Building Bulletin 2015
- Partner News - 2016
- Partner News - 2015
- IAVI World AIDS Day 2014 Bulletin
- IAVI HIV R4P Bulletin - October 2014
- Satellite Session: Community
- Satellite Session
- Reception
- Satellite Session
- Satellite Session
- Satellite Session
- IAVI at HIV R4P
- July 2014
- 2013 and Earlier
- 2014
- 2011
- 2013-2012
- COVID-19
- AIDS 2020
- HVAD 2020
